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Tissue transglutaminase (tTG) is a dual functional acyl transferase/GTPase that has 
important roles in many cellular processes, as well as in the development of various disease 
states.  Here we show that tTG expression is frequently up-regulated in high-grade brain tumors 
or Glioblastoma (GBM), and that tTG is essential for the growth and survival of these highly 
aggressive cancer cells.  We discovered a novel mechanism through which tTG mediates the 
transformed phenotypes of GBMs, which involves its ability to enhance the signaling activity of 
the cell surface receptor tyrosine kinase and proto-oncogene, the epidermal growth factor 
receptor (EGFR).  In particular, tTG can associate with and functionally inactivate the E3 
ubiquitin ligase c-Cbl, a negative regulator of EGFR, thus delaying its downregulation and 
extending its signaling half-life.  Interestingly, the ability of tTG to influence c-Cbl function is 
independent of its crosslinking activity, but dependent on a specific conformation that tTG 
adopts. 
X-ray crystallographic studies showed that tTG can exist in a nucleotide-bound, 
crosslinking inactive closed conformation, or a nucleotide free, crosslinking competent, open 
conformation.  Previous findings from my first study and by others showed that ectopically 
expressed forms of tTG that adopt a closed conformation in cells, promote cell growth and 
survival, whereas tTG mutants that adopt an open conformation trigger cell death.  Thus, we set 
out to better understand the molecular mechanisms that regulate the transition of tTG between 
 these two different conformational states.  Two pairs of intramolecular hydrogen bonds formed 
between the C-terminal end of tTG and its catalytic core domain were identified and shown to 
play an important role in maintaining tTG in its closed conformation.  Disrupting these 
interactions causes tTG to adopt a constitutively open configuration and trigger cell death.  
Collectively, these new insights into the regulation and function of tTG have not only led to its 
identification as an important player in brain tumor progression, but also raise the possibility that 
developing strategies that cause tTG to adopt an open conformation could be beneficial for the 
treatment of human cancers. 
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!CHAPTER 1 
Overview 
 
Tissue transglutaminase (tTG) is a multi-functional protein that has pleotropic roles in 
mammalian cells under physiological settings, as well as has been implicated in the progression 
of several disease conditions.  Although originally identified in 1957 (1), it has only been in the 
last 10 years or so that an increasing number of findings have revealed a previously 
unappreciated role of tTG in promoting human cancer progression.  Increases in the levels of 
tTG expression have been detected in various types of cancer, including breast, pancreatic and 
ovarian cancer (2-6).  In this thesis, I set out to better understand the mechanisms through which 
tTG contributes to oncogenic transformation.  
The purpose of this chapter is to provide an overview of tTG and tTG-mediated cellular 
processes.  I will begin by giving a brief introduction of the transglutaminase family, followed by 
a more detailed overview of tTG, which is the most well-studied transglutaminase family 
member as well as the focus of this thesis.  The two major activities exhibited by tTG, its 
enzymatic transamidation/crosslinking activity and its GTP-binding/hydrolysis (GTPase) activity, 
will be introduced, and several of the mechanisms that regulate tTG activation will be 
highlighted.  Then I will focus on the roles that tTG has in the development of two disease states, 
neurodegeneration and cancer.  In the second part of this chapter, I will introduce the epidermal 
growth factor receptor (EGFR), a critical driver of human malignancies, especially in brain 
tumors.  This part of the thesis serves to provide the necessary background information that will 
be needed to understand the findings presented in Chapter 2, where I discovered an interesting 
and unexpected connection between EGFR signaling, tTG, and human brain tumor progression.  
1
!The Transglutaminase Family 
Protein glutamine !–glutamyltransferases or transglutaminases (TGs) are a family of 
enzymes that catalyze an irreversible post-translational modification of proteins by forming 
covalent linkages (crosslinks) between two proteins or between a protein and a polyamine (7-9).  
There are a total of nine members in the TG family; TG 1-7, blood clotting factor XIII, and the 
catalytically inactive protein band 4.2 (Table 1.1) (7, 10).  While specific members of this family, 
like TG-1, TG-2, and blood coagulation factor XIII, have been extensively studied and are 
relatively well characterized in terms of their tissue distribution and function, others (i.e. TG-3, 
TG-4, TG-7, and band 4.2) are not.  Collectively, TGs are known to play important roles in 
numerous physiological processes, including blood coagulation, cell envelope formation, bone 
ossification, spermatogenesis, and heart development (7, 11).  However, deregulation of these 
enzymes is also associated with a number of human disease states, including autoimmune 
disorders, cancer, infectious diseases, and neurodegenerative disorders (7, 12, 13).  
For example, blood clotting factor XIII is a transglutaminase that plays an essential role 
in the formation of blood clots.  Factor XIII is expressed in the plasma of animals, and it 
circulates throughout the body as a tetrameric proenzyme (factor XIII-A2B2) composed of two 
catalytic A subunits and two non-catalytic carrier B subunits held together by non-covalent 
bonds (14).  This proenzyme is converted to a catalytically active enzyme (XIIIa) via thrombin 
cleavage of the A subunits followed by its Ca2+-dependent dissociation from the regulatory B 
subunits.  Once the A subunit active site is exposed, the activated factor XIIIa functions by 
forming !-glutamyl-"-lysyl amide crosslinks between fibrin molecules to form stable and 
insoluble blood clots.  Mutations in the genes encoding the A subunit or the B subunit of factor 
2
Table 1.1.  Mammalian transglutaminases and their major functions. 
The nine different members of the transglutaminase family and their tissue distribution, 
cellular localization and primary functions are listed.  {Adapted from (7,10)} 
 
  
3
4
!XIII are often causes of a class of blood disorders that are characterized by the formation of 
unstable blood clots and excessive hemorrhage (15).  
TG-1, also known as keratinocyte transglutaminase, is another member of the 
transglutaminase family and is involved in the formation of the cornified cell envelope.  By 
crosslinking keratin, incolucrin, lricrin and other structural proteins, TG-1 promotes the 
formation of the insoluble cornified cell envelope structure, which surrounds skin cells and 
protects them against water loss and infection (16).  Inactivating mutations in the gene encoding 
TG-1 causes the impaired formation and the instability of the cornified cell envelopes, which is 
the underlying cause of lamellar ichthyosis, a skin disorder that is characterized by scaly and 
inflamed skin (17, 18). 
 
Tissue Transglutaminase: An Important Member of the TG Family  
TG-2, which is also referred to as TG-C, TG II, TGase or tissue transglutaminase (tTG) (I 
will refer to it as tTG throughout the rest of my thesis), is a unique and rather important member 
of the TG family.  It is the most ubiquitously and highly expressed form of all the TG family 
members, making it the focus of numerous studies.  In addition to its conserved 
transamidation/crosslinking activity, tTG is also capable of carrying out several additional 
activities, including binding and hydrolyzing GTP (GTPase activity), deaminating proteins, 
functioning as a serine/threonine protein kinase, and generating protein disulfide bonds (19).  
Human tTG is a monomeric protein of 687 amino acids composed of four distinct 
domains; namely the N-terminal !-sandwich (residues 1-139), the catalytic core (residues 140-
454), and two C-terminal !-barrel domains (!-barrel 1; residues 479-585, and !-barrel 2; residues 
586-687) (Figure 1.1) (20, 21).  The catalytic core domain of tTG contains the substrate binding 
5
Figure 1.1.  Domain organization of tissue transglutaminase. 
The four distinct domains of tTG; the N-terminal !-sandwich domain, the catalytic core 
domain, and the two C-terminal !-barrel domains (!-barrel1 and !-barrel2) are shown.  
The amino acids that make up each domain are indicated.  The catalytic triad, residues 
involved in binding Ca2+, and residues involved in binding GTP or GDP are listed and 
highlighted in red, blue and orange, respectively. (7, 20, 21, 36, 38) 
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!pocket, as well as the highly conserved catalytic triad that is essential for the transamidation 
activity of all crosslinking-active TGs.  This catalytic triad in tTG, as well as in other TGs, is 
similar to that seen in cysteine proteinases (i.e. caspases), and includes cysteine 277, histidine 
335, and aspartate 358 (7).  Importantly, mutation of any one of these residues generates a 
catalytically defective form of the enzyme.  For example, the only catalytically inactive member 
of TG family is the erythrocyte membrane protein band 4.2, which harbors substitutions at all 
three sites of the catalytic triad (22).  Moreover, mutating cysteine 277 to a valine in tTG (tTG 
C277V) completely abolishes its enzymatic activity (23).  
tTG’s transamidation activity has been implicated in a wide range of cellular processes, 
including axonal growth, bone development, wound healing, blood vessel formation 
(angiogenesis), cellular differentiation, and apoptosis (24-30).  In the transamidation reaction 
catalyzed by tTG, the active site cysteine residue reacts with the !-carboxamide group of an 
incoming glutamine residue of a protein/peptide substrate to yield a thioacyl-enzyme 
intermediate and ammonia.  The thioacyl-enzyme intermediate then reacts with a nucleophilic 
primary amine substrate, resulting in the covalent attachment of the amine-containing donor to 
the glutamine acceptor substrate and regeneration of the cysteine residue at the active site (Figure 
1.2A).  The end product of the transamidation reaction catalyzed by tTG is the formation of an 
isopeptide bond between two proteins and the release of ammonia.  Importantly, these crosslinks 
are very stable and resistant to mechanical challenges and proteolytic degradation.  
Another activity of tTG is its ability to bind to and hydrolyze GTP, similar to the classical 
guanine nucleotide-binding proteins (G-proteins).  G-proteins function as molecular switches and 
transition between a GTP-bound active state and a GDP-bound inactive state (31).  The ability of 
G-proteins to go between these two states is critical for transducing signals that regulate a myriad 
8
Figure 1.2.  The transamidation and GTPase activities of tTG. 
(A) tTG-catalyzed transamidation reaction.  In the first step, the active site cysteine of 
tTG reacts with the peptidyl glutamine substrate to form a thioester intermediate and a 
molecule of ammonia.  The thioester intermediate then undergoes a nucleophilic attack 
by a second protein with a free !-amino lysine group or by a polyamine.  A stable 
isopeptide bond is then generated between the two substrates and the active site cysteine 
from the enzyme is recovered and released. 
(B) Stimulation of transmembrane GPCRs induces the exchange of GDP for GTP on tTG 
and activates tTG’s signaling activity.  The GTP-bound form of tTG then activates 
PLC"1, which subsequently catalyzes the hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) to diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3), 
causing an increase in the intracellular Ca2+ concentration. 
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!of cellular events.  tTG was initially identified and characterized as an atypical, high-molecular 
weight G-protein, know as Gh#, which mediates signaling from the #1B-adrenergic receptor 
expressed on the cell surface to phospholipase C (PLC$-1) (Figure 1.2B) (32).  Subsequently, the 
GTP-bound form of tTG was shown to also mediate the activation of Ca2+-activated K+ channels 
in vascular smooth muscle cells (33).   
However, the GTP-binding site of tTG is unique amongst the GTP-binding superfamily 
of proteins, sharing no homology with the hetero-trimeric G-proteins or the small G-proteins.  
Specifically, in both the large and small GTPases, there is a highly conserved phosphate-binding 
loop (P-loop) that is essential for binding to the phosphate moiety of the guanine nucleotide (34).  
The crystal structure of the nucleotide-binding pocket of the small GTPase Cdc42 bound to a 
GTP analog (GMP-PCP), with its P-loop highlighted, is shown as an example in Figure 1.3A 
(35).  In contrast, tTG has a unique guanine nucleotide binding domain composed of a stretch of 
positively charged residues, including Arg 476, Arg 478 and Arg 580, which contribute to GTP 
or GDP binding (Figure 1.1 and 1.3B).  One of the most important of these residues is Arg580, 
which forms three hydrogen bonds, one with the guanine ring, one with the #-phosphate, and the 
last with the %-phosphate of the GDP molecule (Figure 1.3B, right panel).  Mutation of this 
arginine to a lysine residue (tTG R580K) results in a form of tTG that is no longer able to bind 
GTP (36). 
 
Regulation of tTG Activities 
tTG’s enzymatic transamidation activity is highly regulated and several co-factors have 
been identified that influence its activity, including Ca2+ and GTP or GDP (20, 36-40).  In vitro 
transamidation assays require millimolar concentrations of Ca2+ to fully activate tTG’s 
11
Figure 1.3.  Comparison of the nucleotide binding pocket between Cdc42 and tTG.  
(A) Close-up view of the nucleotide binding site from the x-ray crystal structure of Cdc42 
bound to a GTP analog (GMP-PCP) (PDB: 2QRZ).  GMP-PCP is shown in sticks, and 
the residues coordinating nucleotide binding (the P-loop) are highlighted in green. (35)   
(B) Close-up view of the nucleotide binding site from the x-ray crystal structure of tTG 
bound to GDP (PDB: 1KV3).  In this structure, GDP is shown in sticks, and the residues 
coordinating GDP binding are highlighted in green.  Interactions between GDP and 
several key residues in the nucleotide binding pocket of tTG are also highlighted.  Polar 
contacts between GDP and these residues are colored in red. (21) 
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!transamidation activity (37).  Incubation of human recombinant tTG with increasing 
concentrations of GDP or GTP!S, a non-hydrolyzable form of GTP, showed a dose-dependent 
inhibition of tTG’s transamidation activity, suggesting that the binding of GTP or GDP to tTG 
negatively regulates its crosslinking activity (36, 37).  Subsequent x-ray crystallographic studies 
performed on tTG by our laboratory in collaboration with John Clardy’s group showed that the 
regulation of the transamidation and the GTPase activities of tTG is achieved via allosteric 
conformational changes that occur within the enzyme following the binding of Ca2+ and 
GTP/GDP (21).   
The x-ray crystal structure of tTG bound to GDP shows that the guanine nucleotide-
binding site of tTG is located in a cleft between the catalytic core domain and the first %-barrel 
(Figure 1.4, left panel).  In this structure, tTG assumes a compact or “closed” conformation 
where the C-terminal %-barrels (%-barrel 1 and %-barrel 2) fold over and block the access of 
substrates to its active site located in the catalytic core domain.  Because substrates cannot access 
the active site of the enzyme, this “closed” conformation of tTG is considered to be 
enzymatically inactive.  However, in another x-ray crystal structure solved when tTG was in a 
nucleotide-free state and bound irreversibly to a peptide that mimics a natural substrate, tTG 
assumes an extended or “open” conformation where the two %-barrel domains swing away from 
the core domain and expose the active site for interactions with glutamine containing substrates 
(Figure 1.4, right panel) (41).  Thus, this conformational state of tTG is believed to be the 
enzymatically active state.  
Ca2+ plays a key role in facilitating tTG’s transition from the “closed”, inactive 
conformation to the “open”, active conformation (20, 37).  Although Ca2+ was not found in any 
of the tTG structures, human TG-3 has been co-crystalized with Ca2+ (42).  By comparing 
14
Figure 1.4.  Two x-ray Crystal structures of tTG. 
The crystal structures of tTG bound to GDP (left) (PDB: 1KV3) and covalently modified 
with an inflammatory peptide (right) (PDB: 2Q3Z) are shown.  GDP and the 
inflammatory peptide in each structure are shown in sticks and colored in blue and red.  
The four domains of tTG, including the N-terminal !-sandwich domain (N), the catalytic 
core domain (Core), the !-barrel 1 domain (!1) and the !-barrel 2 domain (!2), are 
colored in blue, green, orange and red, respectively.  Cartoons representing the 
organization of the four domains of tTG in each of the structures are also shown. (21, 41) 
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!computational models of tTG with TG-3 bound to Ca2+, our group identified three distinct Ca2+-
binding sites in tTG (38).  These include Site-I (Asn229/Asp233), Site-II (Asp306/Asn310) and 
Site-III (Asn398/Glu447) (Figure 1.1) (38).  Studies showed that mutation of any of these sites 
could inhibit the ability of tTG to crosslink proteins, but they did so to different extents.  
Mutation of Site-II had the strongest effects on blocking tTG’s transamidation activity, while 
mutations of Site-I and Site-III had more modest effects.  
 
Regulation of tTG Expression 
Another important way that tTG activity is regulated is through the regulation of its 
expression.  In certain cell lines (i.e. NIH3T3 mouse fibroblasts, HEK293T human embryonic 
kidney cells, and SKBR3 human breast cancer cells), tTG is expressed at very low or 
undetectable levels.  However, prolonged exposure of any of these cell lines to a variety of 
differentiation factors, pro-inflammatory cytokines, growth factors, or hypoxia can up-regulate 
tTG expression (26, 43-46).  Moreover, in many other cancer cell lines, especially those that are 
highly aggressive and metastatic, tTG is constitutively expressed.  For example, the human HeLa 
cervical carcinoma cells, U87 glioblastoma cells, and the MDAMB-231 breast cancer cells all 
express inordinately high levels of tTG.  
Retinoic acid (RA) is one of the best known factors that up-regulate tTG expression (26, 
47, 48).  RA functions as a ligand for the retinoic acid receptors (RARs).  Upon binding to RA, 
RARs become activated and associate with specific sites within the promoter regions of RA-
responsive genes known as the retinoic acid response elements (RARE-motifs) and stimulate 
gene transcription (49).  In the case of tTG, a RARE-motif was identified in the TGM2 promoter 
~1.7 kb upstream of the transcription start site (50).  Mutational studies where the RARE motifs 
17
!in the TGM2 promoter were deleted, blocked the ability of RA to induce tTG transcription, 
highlighting the importance of these elements in the regulation of tTG expression.  Importantly, 
the induction of tTG expression by RA was shown to play an important role in maintaining cell 
viability during RA-induced cellular differentiation (26).  This topic will be discussed in more 
detail later in this chapter.  
Activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF&B) 
signaling pathway was also shown to increase tTG mRNA levels in hepatocytes in response to 
chemical injury or tumor necrosis factor # (TNF#) stimulation (51, 52).  NF&B is a widely 
expressed transcription factor that is typically bound to its negative regulator inhibitor of &B 
(I&B#) in the cytosol of unstimulated cells (53).  However, upon stimulation of cells with a 
variety of growth factors or exposing them to stresses, NF&B rapidly dissociates from I&B# and 
translocates to the nucleus, where it induces the expression of a specific set of genes that 
promote cell survival and cell growth.  A cognate response element for NF&B was found in the 
TGM2 promoter ~1.3 kb upstream of the transcription start site (48).  Excessive activation of the 
NF&B pathway may play a particularly important role in inducing tTG expression during 
inflammation and in many types of cancer cells, which will be further discussed later in this 
chapter (54). 
Activation of the epidermal growth factor receptor (EGFR) signaling pathway, which is 
often de-regulated in human malignancies, is also a known regulator of tTG expression in human 
breast and brain cancer cells.  For example, tTG was identified in a proteomic screen as one of 
the most highly up-regulated proteins in U87 glioblastoma cells exogenously expressing a 
constitutively active and highly oncogenic mutant form of the EGFR known as the EGFR variant 
type III (EGFRvIII) (55).  Likewise, prolonged exposure of SKBR3 breast cancer cells to 
18
!epidermal growth factor (EGF) strongly up-regulated tTG expression and activation from the 
nearly undetectable levels that are normally seen in these cells (43).  It was also shown by our 
laboratory that the combined activation of Ras and Cdc42 downstream of the EGFR, leading to 
the activation of the phosphatidylinositide 3-kinase (PI3K) and NF&B signaling pathways, was 
important for the ability of EGF to up-regulate tTG expression (23).  Increasing the levels of tTG 
expression and/or activation by EGF in different cancer cell lines was shown to be essential for 
EGF-mediated cell migration, invasion and anchorage-independent growth, cellular effects 
which will be described in more detail later in this chapter (23, 43, 56).  In chapter 2, a novel role 
for tTG in extending EGFR signaling and promoting brain tumor progression will also be 
discussed.   
 
The Cellular Localization of tTG  
tTG in the Cytosolic Compartment 
tTG is expressed in several different compartments within the cell, as well as outside the 
cell.  A majority (~80%) of the tTG is present in the cytosol (57, 58).  It has been suggested that 
cytosolic tTG is primarily in the “closed” inactive conformation, due to the low concentration of 
Ca2+ (~100 nM) and the high concentration of GTP (~100 µM) generally found in the cytosol 
(59).  It has been proposed that the cytosolic pool of tTG can become enzymatically activated in 
response to cellular stresses, which frequently results in energy depletion, decreases in GTP 
levels, and the release of Ca2+ from the endoplasmic reticulum (ER) into the cytosol.  The net 
result of these effects triggers the opening of tTG, making its active site accessible to substrates.  
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!tTG in the Nucleus 
Subcellular fractionation studies demonstrated that approximately 5-7% of all the tTG 
expressed in a cell resides in the nucleus (57).  Several factors, including elevating the levels of 
intracellular Ca2+, RA treatment, or vascular endothelial growth factor (VEGF) stimulation of 
endothelial cells, were shown to cause a small amount of tTG to translocate to the nucleus (57, 
60, 61).  Two putative nuclear localization sequences (NLSs) were identified in tTG (amino 
acids 259-263 and 597-602) (62).  However, forms of tTG in which the NLSs were mutated still 
localized to the nucleus like wild type tTG, indicating that the NLSs in tTG are not essential for 
its trafficking into the nucleus (63).  Importin-# 3, a nuclear transport protein, was found to 
associate with tTG both in vitro and in vivo, raising the possibility that tTG might bind Importin-
# 3 as a means to translocate to the nucleus (62).  
Even though only a small percentage of the tTG expressed in cells is found in the nucleus 
(~ 5%), nearly ~15% of tTG substrates identified to date are nuclear proteins, suggesting that this 
small pool of tTG may play important roles in various cellular processes (10, 57).  This appears 
to be the case, as tTG-mediated crosslinking of core histones was shown to promote the 
condensation of chromatin during apoptosis (64, 65).  Another example of a nuclear substrate of 
tTG is the tumor suppressor retinoblastoma (RB) protein, a well-known regulator of cell cycle 
progression and cellular differentiation (66).  RB is a target of caspase-mediated degradation in 
p53-induced apoptosis, and RB-knockout mice are embryonic lethal and exhibit elevated levels 
of apoptosis in the developing retina and throughout the nervous system (67, 68).  During RA-
induced differentiation of erythroleukemia cells, tTG was shown to protect RB from caspase 
degradation in a transamidation-dependent fashion (27).  This finding indicates that tTG may 
protect cells from undergoing apoptosis by modifying RB during RA-induced cellular 
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!differentiation.  More recently, it has also been shown that nuclear localized tTG may play 
critical roles in the broad transcriptional dysregulation that occurs in the mouse model of 
Huntington’s disease (63).  In this case, tTG is thought to regulate the expression of genes 
important in regulating cell metabolism either by directly associating with core histones and 
inhibiting transcription, or by crosslinking chromatin.  
 
Extracellular tTG  
The !-glutamyl-"-lysine bonds formed as a result of tTG’s transamidation activity have 
also been detected in the extracellular matrix (ECM), indicating that tTG can be externalized 
from cells (24, 69).  Nearly every major ECM protein are known substrates of tTG, including 
fibrinogen, fibronectin, and collagen (70).  tTG’s localization in the ECM plays important roles 
in promoting cell adhesion, migration, and ECM organization and turnover, with these effects 
having important consequences in physiological processes, ranging from normal wound healing 
to tissue regeneration.  For example, tTG-mediated crosslinking of fibronectin to itself was 
shown to increase the rigidity or stiffness of fibronectin polymers and promote cell attachment 
(71).  tTG can similarly crosslink and stiffen fibrinogen and collagen fibers (72, 73).  The net 
result of these ECM crosslinking events is amplified integrin receptor clustering and focal 
adhesion formation on the cells that are attached to the ECM, which leads to elevated integrin 
signaling and activation of downstream focal adhesion kinase (FAK) and extracellular signal-
regulated kinase (ERK) (73).  Activation of FAK and ERK are known to regulate cell spreading 
and migration, but they also promote cell growth and survival.  Thus, tTG modified ECM can 
impact a number of cellular processes. 
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!tTG is also a regulator of transforming growth factor % (TGF%) maturation, which is a 
key event during ECM remodeling (74).  TGF% has been shown to increase the synthesis and 
secretion of major ECM proteins (i.e. collagen and fibronectin), and inhibit the proteolytic 
degradation of matrix proteins by reducing the activities of proteases that act on ECM (i.e. 
collagenase and plasminogen activator) (75).  Under basal conditions, TGF% is associated with 
latency-associated peptide (LAP) and latent TGF%-binding protein (LBTP) in a complex in the 
ECM.  tTG was shown to covalently crosslink LBTP to ECM proteins such as fibronectin, thus 
promoting the release of TGF% into the ECM and leading to its reorganization (7, 76, 77). 
The findings from several studies have established that, in addition to modifying cellular 
behavior/outcomes by reshaping the ECM via its enzymatic transamidation activity, tTG also 
exhibits an important non-enzymatic adaptor/scaffold function in cells by promoting the 
formation of a complex between transmembrane receptors expressed on the cell surface and the 
ECM.  For example, tTG can associate with the cell adhesion receptors, integrins (especially %1-
integrins), and promote cell attachment to the ECM by bridging %1-integrin and fibronectin 
interactions (78).  The tTG-%1-integrin-fibronectin complex formation drives integrin clustering 
and activation of downstream signaling events, including the activation of FAK, c-Src tyrosine 
kinase, RhoA and Rho-associated protein kinase (ROCK) (79, 80).  In fibroblasts and vascular 
smooth muscle cells, tTG has also been shown to enhance the association of integrins and the 
platelet-derived growth factor receptor (PDGFR), leading to enhanced PDGFR clustering and 
downstream signaling (81, 82).  Thus, it is clear that under certain circumstances, tTG can 
function as a scaffold. 
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!The Mechanism Through Which tTG Is Released From Cells 
tTG is constitutively secreted from a wide range of cell types (79, 80, 83).  However, it 
contains none of the classical secretory signal sequences, nor does it have any hydrophobic 
domains that are associated with classically secreted proteins, suggesting that tTG is not secreted 
from cells via the classical secretory pathways that involve the ER and Golgi apparatus (7, 79, 
84).  Consistent with this idea, treatment of cells with brefeldin A (BFA) or Exo1, inhibitors of 
classical secretion pathways, did not block the release of tTG from cells (85).  
The mechanism of tTG externalization from cells remained largely unknown until just 
recently.  Studies by our laboratory have discovered a rather surprising way that tTG is secreted 
from cells, which involves the generation of plasma membrane-derived microvesicles (MVs) 
(85).  MVs are extracellular vesicular structures that are formed and shed directly from the 
surfaces of cells (86).  They contain a variety of cargo that is not typically thought to be released 
from viable (healthy) cells, including cell-surface receptor tyrosine kinases, metabolic enzymes, 
RNA transcripts, and microRNAs (85, 87-89).  Once released from a donor cell (the cell that 
generates the MV), the MVs can then be taken up by recipient cells and impact their behaviors 
(86).  The transfer of epigenetic information between two cells via MVs represents a novel form 
of cell-to-cell communication believed to be utilized by all cell types, and especially by 
aggressive forms of human cancer cells (90).  Studies by our group have shown that tTG is a 
major protein component of cancer cell-derived MVs and that its transfer to normal recipient 
cells (i.e. NIH3T3 fibroblasts and non-transforming MCF10A mammary epithelial cells) caused 
them to exhibit a transformed phenotype, including increased cell survival and the induction of 
anchorage-independent growth (85).  tTG was shown to both bind to and crosslink fibronectin 
(making a constitutive fibronectin dimer) on the surfaces of these vesicles, which was essential 
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!for their ability to transform normal fibroblasts and mammary epithelial cells (85).  These 
findings highlighted at least one mechanism by which tTG can be externalized from cells, and 
showed that MV-mediated communication between cells might play an important role in cell 
transformation and cancer progression.   
 
tTG in the Mitochondria 
Emerging evidence suggests that tTG might also be expressed in the mitochondria.  
While tTG does not contain the classical N-terminal mitochondrial targeting sequence found in 
many proteins that reside in the mitochondria, it has been shown by immunofluorescent 
microscopy and cell fractionation studies to localize to the mitochondria in various cell types (91, 
92).  Further evidence that tTG associates with the mitochondria comes from studies using tTG 
knock-out (KO) mice.  tTG KO mice are viable, grow to normal size, and show no reproductive 
defects (93, 94).  However, these animals have impaired ATP production, particularly after being 
challenged with exercise (95).  Moreover, while under normal cellular conditions, tTG activity is 
tightly regulated, its expression and activation are often increased in several disease conditions 
that are characterized by mitochondrial dysfunction, including cardiovascular ischemia and 
neurodegenerative disorders (96, 97).  The role of tTG in the pathogenesis of several forms of 
neurodegenerative disorders will be further discussed in the next section. 
An eight amino acid stretch in tTG (amino acids 204-211) that shares 70% identity with 
the Bcl-homology 3 (BH3) domain of B-cell lymphoma-2 (Bcl-2) was recently identified (92).  
Since Bcl-2 is a protein that localizes to the mitochondria and regulates the apoptotic responses 
in cells, the possibility that tTG may similarly be localized to the mitochondria via this domain 
and involved in apoptosis was proposed. In line with this idea, tTG was shown to interact with 
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!the pro-apoptotic protein Bcl-2 associated X protein (Bax), but not with the anti-apoptotic 
protein Bcl-2 (92).  Bax also serves as a major substrate for tTG-mediated crosslinking in the 
mitochondria.  tTG-induced hyperpolarization of the mitochondrial membrane sensitizes cells to 
programmed cell death (91).  Over-expression of tTG in neural cells resulted in a much more 
rapid induction of cell death that was accompanied by morphological changes to the 
mitochondria, which included clustering of the mitochondria, reduced cristae size, and an 
extremely electron-dense matrix (91).  Collectively, these findings point to a possible connection 
that may exist between tTG localized to the mitochondria and cellular metabolism and the 
regulation of cell death. 
 
tTG and Neurodegenerative Diseases 
Neurodegenerative disorders include a number of chronic conditions that are 
characterized by progressive loss of neurons that ultimately results in the death of the patient 
(98).  A subset of these disorders are characterized by the aggregation of disease-specific 
pathogenic proteins, including Parkinson’s disease (PD), which is characterized by #-synuclein 
aggregation and formation of Lewy bodies, Alzheimer’s disease (AD), which is characterized by 
% amyloid and tau aggregation, and Huntington’s disease (HD), which is characterized by mutant 
huntingtin protein aggregation (99).  Protein aggregate (aggresome) formation in cells is 
generally believed to function as a protective mechanism to deal with a large amount of 
misfolded or damaged proteins that have failed to be eliminated by the ubiquitin proteasome 
system and have accumulated in the cell (100).  Thus, by forming protein aggregates, the 
cytotoxic effects of these misfolded proteins are minimized.  However, once the aggregates reach 
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!a certain size, they begin to interfere with essential cellular processes and cause neuronal cell 
death (101).  
Elevated expression and activation of tTG are frequently observed in HD, AD, and PD 
patients (99).  Depletion of energy and increases in the cytosolic Ca2+ levels in these diseased 
cells are believed to induce tTG to adopt an “open”, crosslinking competent state (102).  The 
covalent crosslinking of pathogenic proteins by tTG into large proteinaceous aggregates are a 
recurring theme in PD, AD, and HD, and the use of tTG expression and activation have been 
proposed as a diagnostic marker for these diseases (98).  
Among the different neurodegenerative disorders that tTG has been associated with, it 
has been most heavily studied in HD.  The hungtingtin (htt) protein normally contains a 
polyglutamine tract that ranges from 6-35 glutamine residues (103).  However, when the 
polyglutamine repeat is expanded by just one glutamine residue (36 glutamines), htt becomes 
pathogenic.  This number of repeats can be as large as 250 glutamine residues in a row, and the 
length of the glutamine tract directly correlates to the severity of the disease symptoms (104-106).  
Interestingly, tTG can not crosslink a htt protein containing a normal number of glutamines 
(from 6-35), however, htt proteins of pathological length can be crosslinked by tTG (103, 107, 
108).  Moreover, tTG activity is increased in HD brain tissue, and it colocalizes with htt 
aggregates in the nucleus, suggesting a direct involvement of tTG in htt aggregate formation 
(109, 110).  In mouse models of HD, treatment with a tTG inhibitor, cystamine, reduces htt 
aggregate formation in the cortex and striatum, and extends the life of these animals (111, 112).  
Crossing the tTG knock-out mouse strain with the HD mouse model resulted in a mouse line that 
exhibits improved motor performance, prolonged survival and decreased cell death compared to 
the control HD mice (113).  More recently, tTG has been implicated in the broad transcriptional 
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!dysregulation in the mouse model of HD, including repression of genes that control 
mitochondrial metabolic functions, such as cytochrome c and peroxisome proliferator-activated 
receptor-! coactivator (PGC)-1#, indicating that tTG may contribute to several aspects of HD 
development (63). 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is another 
disease in which tTG has been implicated (96).  % amyloid and tau are the two proteins that have 
been most often linked to the development of AD.  Evidence from in vitro and cell culture based 
studies have shown that tTG can crosslink both tau and % amyloid (96).  Elevated tTG expression 
combined with its co-localization with tau and % amyloid aggregates in AD brains further suggest 
a role for tTG in the development/progression of AD (114).  Moreover, a splice variant of tTG, 
called tTG-Short (tTG-S), is commonly found in AD brains, while being virtually undetectable 
in control normal brains (115-117).  tTG-S lacks the C-terminal 138 amino acids that correspond 
to the auto-inhibitory C-terminal domain, and it exhibits greatly reduced transamidation activity 
and GTP binding activity (115).  Studies from our group showed that this truncated form of tTG 
exerts diametrically opposite effects on cell viability compared with full-length tTG, as full-
length tTG confers a strong survival advantage to cells whereas tTG-S is apoptotic (115).  
Several ongoing studies are focused on this isoform of tTG in the pathology of AD.   
 
tTG in Cancer Progression 
As little as a decade ago, tTG was generally believed to promote cellular differentiation 
or to induce apoptosis.  However, a growing body of evidence suggests a very different role for 
tTG in human cancers.  For example, tTG is over-expressed in various forms of human cancer, 
where it participates in an array of cellular processes/events that are intimately linked to cancer 
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!progression, including promoting cell growth and survival, as well as driving cell migration and 
invasion. 
 
tTG in Cell Migration and Invasion 
A number of studies have demonstrated a role for tTG in promoting cell migration.  The 
ability of tTG to promote cell attachment and movement depends in part upon its capacity to 
interact with integrin and fibronectin.  The formation of tTG-integrin-fibronectin complexes, 
where tTG works to bring integrin and fibronectin together more efficiently, stimulates the 
activity of signaling proteins that are intimately linked to cell migration, including FAK, the 
MAP kinase ERK, and the small GTPase RhoA (78-80).  tTG has also been shown to crosslink 
ECM proteins (i.e. fibronectin and collagen), increasing the rigidity of the ECM, which promotes 
integrin clustering and activation, and stimulates cell migration (71-73).  tTG can also potentiate 
the ability of growth factors to activate signaling events.  It does so by interacting with growth 
factor receptors such as the PDGFR, and mediating their association with integrins to enhance 
the efficiency of PDGF-induced signaling events (81, 82).  
Our laboratory identified tTG as an important mediator of EGF-stimulated HeLa cervical 
carcinoma cell migration and invasion (56). EGF stimulates the activation of tTG in HeLa cells 
without having a significant effect on its expression.  Blocking the activity of tTG in HeLa cells 
by exposing them to the tTG inhibitor monodansyl cadaverine (MDC), or knocking-down tTG 
expression by siRNA, potently inhibited EGF-stimulated cell migration.  This initial study was 
then followed-up by another study that showed EGF stimulation caused a rapid accumulation of 
tTG to the leading edges of cells (118).  Leading edges are plasma membrane protrusions that 
extend from the cell body in the direction of movement, providing the necessary adhesion that a 
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!cell needs to move forward (119).  It was then shown that the redistribution of tTG to the leading 
edges depends on the ability of tTG to interact with the chaperone heat shock protein 70 (Hsp70).  
Blocking Hsp70 activity using the specific inhibitors myricetin or VER 155008 prevented tTG’s 
localization to the leading edge and blocked cell migration.  
In addition to being important in cell migration, tTG is also required for the invasive 
activity exhibited by some highly aggressive human cancer cells.  The first indication that this 
might be the case came from a study in which tTG was identified in a proteomic screen as one of 
only eleven proteins that were consistently up-regulated in metastatic human lung and breast 
tumors (120, 121).  Moreover, work by our laboratory showed that tTG was preferentially over-
expressed in primary breast tumors and breast cancer cell lines that are highly invasive and 
metastatic (i.e. the MDA-MB-231 human breast cancer cell line) (43).  The ectopic expression of 
tTG in MCF10A, a non-transformed mammary epithelial cell line, was shown to be sufficient to 
induce the epithelial to mesenchymal transition (EMT), a process in which epithelial cells lose 
their typical cell polarity and cell-cell adhesion properties and acquire a more mesenchymal-like 
migratory and invasive phenotype (122, 123).  tTG expression in these normal mammary 
epithelial cells leads to the signature loss of epithelial-specific markers (i.e. E-cadherin and %-
catenin), and the up-regulation of mesenchymal markers, such as fibronectin, and N-cadherin, as 
well as the transcriptional repressors Twist1, Zeb1, and Zeb2.  The up-regulation of Zeb1 and the 
switch in the expression from E-cadherin to N-cadherin were shown to result from the tTG-
mediated activation of the NF&B and Akt signaling pathways, respectively.  The tTG-induced 
EMT promoted the detachment of cancer cells from the primary tumor and facilitated their 
migration and metastatic activity.  
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!The Protective Effects of tTG  
Apoptosis is a form of programmed cell death that is initiated through the activation of 
specific intracellular pathways in response to various death stimuli, and it plays critical roles in 
development and normal tissue homeostasis (124).  Interestingly, cancer cells often develop 
ways to limit or circumvent apoptosis, providing them with a selective advantage to grow under 
stressful conditions or when challenged with chemotherapeutic agents.  Based on some early 
findings showing that tTG expression and activation were up-regulated during apoptosis, 
combined with the fact that tTG is frequently over-expressed and/or overactivated in 
neurodegenerative disorders (i.e. AD, HD and PD), it is easy to understand why tTG was initially 
believed to be involved in promoting cell death (98, 125).  However, more recent findings have 
shown that the up-regulation of tTG expression in response to cellular stress is often used to help 
cells cope with the insults rather than promoting cell death.  Moreover, it is now clear that cancer 
cells often hijack tTG and use it to promote cell survival.   
One of the first lines of evidence suggesting that tTG can promote cell survival came 
from a study in our laboratory that was looking at the effects of retinoic acid (RA) treatment on 
cells (26).  We found that the exposure of HL-60 leukemia cells to RA induced tTG expression 
and activation, as well as caused the cells to differentiate into mature granulocytes.  However, 
when the same cells were treated with RA and the tTG inhibitor, MDC, instead of inducing 
cellular differentiation, the cells died, suggesting that the RA-induced tTG activity was important 
for maintaining cell viability during cellular differentiation.  This was further supported by the 
finding that exposing HL60 cells to a synthetically-derived analog of RA that is particularly 
effective at causing cell death, called fenretinide (HPR), triggered an apoptotic response in these 
cells.  It was later shown, that unlike RA, HPR was unable to induce tTG expression.  However, 
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!ectopic expression of tTG in HL-60 cells was sufficient to protect these cells from HPR-induced 
apoptosis.  These findings were some of the first showing that the up-regulation of tTG 
expression and activation did not always result in apoptosis.  Rather, they showed that, at least in 
some cell contexts, tTG can help to tip the balance toward differentiation rather than cell death. 
Over-expression of tTG in human embryonic kidney HEK293T cells was also shown to 
provide protective effects to these cells in response to treatment of the Ca2+ ionophore A23187 
(126).  Increases in the cytosolic Ca2+ levels due to Ca2+ immobilization by A23187 treatment 
increased mitochondrial permeability and cytochrome c release to the cytosol.  These events then 
led to the activation of caspases, which execute their apoptotic functions by cleaving proteins 
that are essential for maintaining cell viability, thus causing cell death (124).  Stable expression 
of tTG in HEK293T cells was shown to be able to block A23187-induced apoptosis by 
preventing mitochondrial membrane depolarization and the release of cytochrome c into the 
cytosol, thus preventing the subsequent activation of caspases (126).  
Several types of breast, pancreatic and brain cancer cell lines that are resistant to 
chemotherapy also tend to have high levels of tTG expression and transamidation activity (2, 
127).  A case in point is the highly aggressive and malignant MDA-MB-231 breast cancer cell 
line, which exhibits inordinately high levels of tTG expression and activation.  Knocking down 
tTG expression in these cancer cells using siRNA or treating them with the transamidation 
inhibitor MDC sensitized the cells to the chemotherapeutic agent doxorubicin (128).  Moreover, 
the survival signaling triggered by the EGFR was also found to be dependent on tTG in some 
cancer cell lines.  For example, the levels of tTG expression and its transamidation activity are 
markedly enhanced in the human SKBR3 breast cancer cell line after they have been stimulated 
with EGF for prolonged (~2 days) period of time (23, 43).  Inhibiting the transamidation activity 
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!of tTG using MDC abolished the ability of the EGFR to protect these cells from doxorubicin-
induced apoptosis, as well as from serum-deprivation-induced apoptosis (43).  Moreover, ectopic 
expression of tTG in SKBR3 breast cancer cells fully mimics the effects of EGF treatment and 
desensitizes them to doxorubicin-induced apoptosis. 
 
tTG and Cell proliferation  
Accumulating evidence suggests that tTG strongly promotes the growth of human cancer 
cells (129).  One mechanism underlying tTG’s ability to promote cell growth involves the 
activation of the transcription factor NF&B (130).  Increases in NF&B signaling have emerged as 
a hallmark of human cancers, and a strong correlation exists between the levels of tTG 
expression and the amount of NF&B activity detected in aggressive and drug-resistant forms of 
breast cancer cells, malignant melanoma cells, and pancreatic cancer cells (127, 130, 131).  As 
discussed in an earlier section, the ability of NF&B to function as a transcription factor and 
regulate the expression of genes that promote cell growth and survival is normally kept in check 
by its retention in the cytosol where it is bound to its negative regulator I&B# (53).  Exposure of 
cells to a variety of growth factors and cell stresses results in the rapid phosphorylation and 
degradation of I&B#, thus freeing NF&B to enter the nucleus and influence gene expression.  
Importantly, tTG was shown to de-regulate NF&B signaling by binding to and crosslinking I&B# 
both in vitro and in vivo (130).  The tTG-mediated modification of I&B# reduced its binding 
affinity for NF&B, thus resulting in the constitutive activation of NF&B transcriptional activity 
and promoting cell growth. 
tTG is also important for the ability of EGF to stimulate the growth of breast cancer cells 
(23).  Exposing the human SKBR3 breast cancer cell line to EGF promoted their growth in 
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!monolayer, as well as their ability to form colonies in soft agar, an in vitro measure of 
tumorigenicity.  Looking for proteins that function downstream of the EGFR to mediate these 
effects led to the identification of tTG as a key player in EGFR signaling.  Our laboratory 
showed that tTG expression was not only up-regulated by EGF stimulation, but that knocking-
down tTG expression with siRNAs or treating cells with the inhibitor MDC completely blocked 
the ability of EGF to promote their growth.  Moreover, the ectopic expression of tTG in SKBR3 
cells was sufficient to mimic the actions of EGF and promote their anchorage-independent 
growth.  The mechanism through which tTG stimulated the growth of these breast cancer cells 
was then identified and involves the ability of tTG to form a complex with the intermediate 
filament protein keratin-19 (K19) and the non-receptor tyrosine kinase Src, which is one of the 
earliest identified oncogenes that contributes to multiple aspects of malignant transformation 
(132).  The tTG-K19-Src complex leads to the activation of Src and enhanced cell growth.  Since 
tTG can impact a number of signaling events that are crucial for cell growth and survival (i.e. 
activating the signaling activities of NF&B and Src), this may start to provide some explanations 
for how tTG can contribute to several different aspects of cancer progression. 
 
Several lines of evidences have highlighted an intricate connection that exists between 
EGFR signaling and tTG, namely that tTG functions as a downstream effector of the EGFR and 
has important roles in EGF-stimulated cancer cell growth and survival (23, 43, 56, 118).  In 
Chapter 2 of this thesis, I will describe another unexpected way that tTG contributes to EGFR 
signaling, which has important consequences in brain cancer progression.  In particular, I have 
found that tTG can help extend the signaling lifetime of the EGFR in some brain tumors.  Given 
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!the importance of tTG in EGFR-driven cancers, I will give a brief overview on EGFR and its 
roles in brain tumor development in the remaining part of this chapter. 
 
Overview Of the Epidermal Growth Factor Receptor (EGFR) 
The EGFR is a receptor tyrosine kinase in the ErbB family, which is comprises four 
closely related members, namely ErbB1/EGFR/HER1, ErbB2/HER2/Neu, ErbB3/HER3 and 
ErbB4/HER4 (133).  The gene encoding the EGFR is located on chromosome 7p11-13 and 
consists of 28 exons (134).  The EGFR is first synthesized as a 1210-residue polypeptide 
precursor that contains an N-terminal membrane targeting sequence (135).  Once trafficked to 
the cell surface, the membrane targeting sequence of the EGFR is cleaved off, resulting in the 
mature 1186-residue EGFR protein product that has a molecular mass of ~170 kDa (136).  
Eleven different ligands for the ErbB family have been identified, among which EGF, 
transforming growth factor # (TGF- #), amphiregulin (AR), heparin-binding growth factor (HB-
EGF), epiregulin (EPR), and betacellulin (BTC) can bind to the EGFR and stimulate its tyrosine 
kinase activity (137, 138). 
The EGFR is composed of a N-terminal cysteine-rich extracellular ligand-binding 
domain, a hydrophobic membrane spanning domain, and a C-terminal intracellular tyrosine 
kinase domain (139).  The extracellular domain of the EGFR can be further divided into four 
domains (I, II, III and IV), and can adopt two distinct conformations that regulate its activation 
(140, 141).  Domains I and III are each ~160 amino acids in length and are responsible for 
binding to activating ligands, such as EGF.  Domains II and IV are cysteine-rich domains each 
consisting of ~150 amino acids that are important for promoting the formation of EGFR 
homodimers or heterodimers with other members of the ErbB family when the receptor is bound 
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Figure 1.5.  The mechanism of EGFR activation. 
(A) Schematic representation of the EGF induced dimerization of the extracellular 
domains of the EGFR.  Ligand (EGF) binding induces the transition of the extracellular 
domain from a tethered auto-inhibited state to an extended conformation.  The 
dimerization arm localized in domain II is exposed in this process, and interacts with the 
dimerization arm from another EGFR, promoting the dimerization of the ligand-bound 
EGFRs.  
(B) General view of the ligand-induced dimerization and activation of EGFR.  EGF 
binding to the extracellular domain of an inactive EGFR monomer induces its 
dimerization with another ligand-bound EGFR.  The cytoplasmic domains of the 
dimerized EGFRs are then brought into close proximity to one another, and interact in an 
asymmetric manner that activates its intrinsic kinase activity.  Specifically, the kinase 
domain of one EGFR phosphorylates the cytoplasmic tail of its dimerization partner.  
These trans-phosphorylation events create docking sites for downstream signaling 
molecules.  A depiction of the major auto-phosphorylation sites in the cytoplasmic 
domain of the EGFR along with the signaling pathways associated with these sites are 
shown in the zoom-in box.  {Adapted from (140, 147)} 
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!to a ligand (142).  The conformational changes that occur within the extracellular domain of the 
EGFR during dimerization is depicted in Figure 1.5 A.  Specifically, before ligand binding, the 
dimerization arm located in domain II is buried by intramolecular interactions with domain IV 
(140, 143, 144).  However, upon binding to EGF, domains I and II rotate and transition from the 
tethered auto-inhibited configuration to an extended configuration, allowing the dimerization 
arm in domain II to interact with a second ligand-bound receptor (140, 141).  
Following dimerization of the extracellular domains of the receptors, the intracellular 
kinase domains dimerize asymmetrically in a head-to-tail orientation.  This results in the 
activation of the intrinsic kinase activity of the EGFR and trans-phosphorylation of specific 
tyrosine residues within its cytoplasmic tail by the partnering receptor (145-147).  These residues 
include Y992, Y1045, Y1068, Y1086, Y1148 and Y1173 (Figure 1.5 B), and their 
phosphorylation provides docking sites for downstream adaptors and effector proteins.  These 
proteins associate with the EGFR through interactions between Src Homolgy 2 (SH2) domains 
or phospho-tyrosine-binding (PTB) motifs on the effector proteins with the phospho-tyrosine 
residues present on the intracellular domain of the EGFR (148, 149).  After binding to the EGFR, 
these adaptor and effector proteins stimulate downstream signaling proteins, including ERK 
(extracellular signal-regulated kinase), PI3K (Phosphoinositide 3-kinase), phospholipase C, 
protein kinase B (AKT), and STAT (signal transducer and activator of transcription), leading to 
enhanced cell growth, angiogenesis, migration, and survival (137, 150). 
Down-regulation of the EGFR signaling activity occurs through a highly regulated, multi-
step process that involves EGFR internalization, ubiquitylation, and degradation in the 
lysosomes (Figure 1.6) (138).  When the EGFR is activated, a phosphorylation event in its 
cytoplasmic domain creates docking sites for the ubiquitin ligase c-Cbl (casitas B-lineage 
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Figure 1.6.  Mechanism of endocytic down-regulation of the EGFR.  
Ligand (EGF)-induced EGFR dimerization and auto-phosphorylation recruits the E3 
ubiquitin ligase c-Cbl to the activated EGFRs.  c-Cbl then catalyzes the ubiquitylation of 
the EGFR, which facilitates the packing of the EGFRs into clathrin-coated endocytic 
vesicles.  The endocytic vesicles first fuse with the sorting endosomes, where the EGFRs 
are sorted depending on their ubiquitylation status.  Ubiquitylated receptors are 
subsequently routed to the multivesicular body (MVB) and targeted for lysosomal 
degradation, while non-ubiquitylated receptors are recycled back to the plasma 
membrane.  {Adapted from (153)} 
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!lymphoma proto-oncogene).  c-Cbl can associate with the EGFR directly by binding to the 
phosphorylated tyrosine residue 1045, or indirectly through the action of another adaptor protein 
named Grb2 (growth factor receptor-bound protein 2) (151, 152).  c-Cbl functions as a ubiquitin 
ligase and catalyzes the ubiquitylation of the EGFR at several lysine residues within its 
cytoplasmic tail, which serves as a sorting motif for targeting activated EGFRs for degradation in 
later steps (153).  During its internalization, the receptor-ligand complex on the cell surface is 
first incorporated into clathrin-coated pits (CCPs) that pinch off from the plasma membrane and 
form the endocytic vesicles.  These endocytic vesicles then fuse with the early endosomes and 
release the receptor-ligand complex into the early endosomes (154).  After its translocation into 
the early endosomes, the receptor can undergo either one of two distinct processes depending on 
its ubiquitylation status (153).  Those receptors that are not ubiquitylated are recycled back to the 
cell surface, while the ubiquitylated receptors are taken up into the multivesicular bodies 
(MVBs) and targeted for lysosomal degradation.  Several studies have shown that activated 
EGFRs continue to recruit and activate intracellular signaling molecules following their 
internalization and trafficking to the endosomes (155-157).  Eventually, the acidic environment 
of the lysosomal lumen causes the ligands to dissociate from the EGFRs.  The receptors are then 
de-phosphorylated, and their signaling activities are terminated (158).  
 
The EGFR and Cancer Progression 
EGFR and its related family members are the major mediators of a complex signaling 
network that regulates normal cell growth, differentiation, adhesion, migration, and survival.  
Studies have shown that EGFR signaling is essential for early embryonic development and in the 
renewal of adult stem cells in different tissues such as the skin, liver and gut (159).  EGFR 
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!knock-out mice exhibited severe developmental defects in the epithelial structures of the skin, 
lung, and the central nervous system (160, 161).  Collectively, these findings underscore the 
importance of EGFR signaling in normal development and in tissue maintenance. 
However, EGFR-mediated signaling is often de-regulated in human cancers.  One of the 
first pieces of evidence supporting a role for the EGFR in promoting oncogenesis came from the 
finding that the product of the v-erbB oncogene from avian erythroblastosis virus corresponds to 
a truncated and constitutively activated form of the EGFR (162).  The gene encoding the EGFR 
was later shown to be amplified and/or mutated in primary human brain tumors (163).  Now it is 
well appreciated that aberrant EGFR signaling plays a key role in cellular transformation, and 
that over-expression and/or overactivation of the EGFR is a hallmark of various types of cancers, 
including breast, colon, pancreas, lung, esophageal, and brain cancers (133).  Several different 
mechanisms can give rise to de-regulated EGFR signaling (164).  The most common one 
involves amplification of the gene encoding the EGFR.  Alternatively, oncogenic EGFR 
signaling can occur through the acquisition of activating mutations in the EGFR gene.  The 
mechanisms leading to aberrant EGFR signaling activities are perhaps most often seen in a type 
of highly aggressive brain tumor known as grade IV astrocytoma or glioblastoma multiforme 
(GBM). 
  
The EGFR in Glioblastoma 
Glioblastoma is the most common and lethal form of adult primary brain tumor and 
accounts for about 50% of all gliomas and 12-15% of all intracranial neoplasms (165).  An 
estimated 17,400 patients are diagnosed with GBM in the United States every year (166).  
According to the world health organization classification system, glioblastoma is categorized as 
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!the highest grade (Grade IV) astrocytoma, which is characterized by a high degree of cellularity, 
anaplasia, vascularization, proliferation, and necrosis (167).  Clinical hallmarks of glioblastoma 
include its aggressive growth and inexorable recurrence despite multimodal therapy regiments 
that include surgery, radiation and chemotherapy (168).  Despite aggressive treatment, the 
prognosis is dismal and median life expectancy of a patient with GBM ranges from 12-15 
months (169).   
Several different proteins have been identified that contribute to GBM formation, 
proliferation, and survival, and are currently being investigated as potential targets in treating 
GBM.  Of these, receptor tyrosine kinases, including the EGFR, PDGFR, and hepatocyte growth 
factor receptor (c-MET), the PI3K pathway, as well as signaling pathways activated by the loss 
of PTEN (phosphatase and tensin homolog) and NF1 (neurofibromin 1), play central roles in the 
pathobiology of glioblastoma (170).  Based on their unique molecular signatures, glioblastomas 
can be further divided into four subtypes (171).  These four different subtypes include: the 
classical subtype, which is characterized by EGFR gene amplification; the mesenchymal subtype, 
which is characterized by NF1 loss; the pro-neural subtype, which has alterations in the PDGFR; 
and the neural subtype, which is typified by the expression of neuron markers such as NEFL and 
GABRA1.  
One of the most common genetic alterations in primary GBM is the over-expression of 
the EGFR, which occurs in up to 60-90% of GBM (165, 167, 170).  Whereas its expression in 
normal cells is estimated to be ~40,000-100,000 receptors per cell (172), in malignant tumors 
EGFR levels may reach 2 million per cell (173).  Approximately 50% of GBMs reportedly have 
EGFR gene amplification, and these tumors invariably over-express the EGFR (163, 174, 175).  
However, EGFR over-expression without gene amplification events has been reported in up to 
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!27% of GBM, suggesting that additional mechanisms that lead to EGFR over-expression must 
exist (176).  Numerous studies have revealed a relationship between aberrant EGFR activity and 
the malignant nature of the glioblastoma cells (177).  For example, EGFR over-expression 
promotes glioma cell proliferation and resistance to radiation therapy (178).  Recent studies have 
also shown an unfavorable prognostic relationship between EGFR gene amplification and overall 
survival in GBM patients (179). 
Besides gene amplification, activating mutations and truncations of the gene encoding the 
EGFR are also common mechanisms leading to excessive EGFR signaling activities in 
glioblastoma.  One such example is the EGFR variant III (EGFRvIII).  Approximately 50% of 
the glioblastomas that over-express wild type EGFR harbor the EGFRvIII mutant, which is 
generated by an in-frame deletion of exons 2-7, resulting in the loss of amino acids 6-273 in the 
extracellular domain of the EGFR (Figure 1.7) (180, 181).  This truncated mutant receptor has a 
molecular mass of ~145 kDa compared with ~170 kDa for wild type EGFR, and is unable to 
bind to EGF due to deletion of most of the ligand-binding site in the extracellular domain (182).  
Despite this, however, the EGFRvIII exhibits constitutive tyrosine kinase activity and is 
defective in down-regulation (183).  The expression of EGFRvIII has been linked to an 
extremely poor prognosis for GBM patients (179, 184).  The ectopic expression of EGFRvIII in 
glioma cell lines induces constitutive activation of the Ras and PI3K signaling pathways (185, 
186).  Constitutively active c-Jun N-terminal kinase (JNK) is also found in EGFRvIII-positive 
cells but not in cells over-expressing wild type EGFR, indicating that the JNK pathway plays an 
important role in cell transformation by EGFRvIII (187).  In addition, EGFRvIII has also been 
shown to enhance wild type EGFR signaling by up-regulating the expression of EGF in 
glioblastoma (188).  Collectively, these signaling events lead to increased cell migration and 
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Figure 1.7.  Comparison of the extracellular domain and the downstream signaling 
pathways between wild type EGFR and EGFRvIII. 
(A) EGFRvIII is characterized by an in-frame deletion of exons 2‒7 of the EGFR gene, 
which results in the loss of amino acids 6 to 273 and a novel glycine residue insertion in 
the extracellular domain.  This mutation yields a form of EGFR that cannot associate 
with ligand but stays constitutively active. 
(B) The major signaling pathways downstream of the ligand activated wild type EGFR 
and the constitutively active EGFRvIII include the PI3K and MAPK (Ras-MEK-ERK) 
signaling pathways.  Binding of EGF to wild type EGFR initiates transient activation of 
the Ras-MEK-ERK pathway, and intermediate activation of the PI3K-Akt-mTOR 
pathway.  Wild type EGFR phosphorylation also results in the recruitment of negative 
regulators such as c-Cbl, which promotes receptor internalization and signal termination.  
Activation of EGFRvIII also leads to activation of the Ras-MEK-ERK pathway.  
However, EGFRvIII activates the PI3K-Akt-mTOR pathway to a larger extent compared 
to wild type EGFR.  EGFRvIII also constitutively activates JNK signaling pathway, 
which is not commonly observed with wild type EGFR.  EGFRvIII also shows defective 
receptor internalization due to decreased complex formation with c-Cbl.  Collectively, 
these effects lead to prolonged and excessive growth signals, which greatly promote 
oncogenic transformation.  {Adapted from (164)} 
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!proliferation, and enhanced resistance to apoptosis induced by DNA-damaging agents, thus 
promoting glioblastoma progression (189, 190). 
The identification of the EGFR as an oncogene has led to the development of therapies 
directed against this receptor.  For example, monoclonal antibodies that bind to and prevent the 
activation of the EGFR, or small molecule inhibitors that block the tyrosine kinase activity of the 
EGFR, have been developed and proven useful in treating certain types of cancers (133).  
However, their use in the treatment of aggressive brain tumors has received limited success.  
Therefore, there continues to be an overriding need to identify other potential therapeutic targets 
for the treatment of these aggressive brain cancers.   
 
Overview of the Thesis 
Considering that tTG functions downstream of the EGFR and that tTG has been shown to 
promote several aspects cancer progression in other cancer cell types, we asked whether tTG 
could also contribute to the malignant transformation of glioblastoma cells.  As described in 
Chapter 2 of this thesis, we found that, indeed, tTG is essential for the oncogenic phenotypes 
exhibited by these aggressive brain tumor cells.  We showed that tTG expression is upregulated 
in high grade human brain tumor samples, and that knocking-down tTG expression in human 
glioblastoma cell lines blocked their oncogenic transformation.  Moreover, we identified an 
unexpected pathway that tTG participates in EGFR signaling in these brain cancer cells.  
Specifically, tTG, in a conformation dependent manner, was able to block the action of the E3 
Ubiquitin ligase c-Cbl and protect the EGFR from down-regulation, thus prolonging its signaling 
lifetime and promoting brain tumor progression.   
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!From previous discoveries and data presented in Chapter 2, we can see that the two 
distinct conformational states of tTG differentially impact its functions. In Chapter 3, we set out 
to examine the molecular mechanisms that regulate the transition of tTG between its two 
functionally distinct states.  We found that intramolecular interactions between the C-terminal 
tail of tTG and its catalytic core domain are important in maintaining tTG in its closed 
conformational state.  Two pairs of hydrogen bonds, formed between residues N681 and K677 in 
the most C-terminal %-barrel domain and residues W254 and D434 localized in the catalytic 
domain, are required to stabilize tTG in its closed conformation.  Disrupting these interactions 
caused tTG to adopt an open conformation that induces apoptosis in cells.   
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 CHAPTER 2 
*A novel mechanism for the up-regulation of EGF-receptor levels in glioblastomas 
 
Abstract 
Tissue transglutaminase (tTG) is a GTP-binding protein/acyl transferase whose 
expression is up-regulated in glioblastoma and associated with decreased patient survival.  Here 
we delineate a unique mechanism by which tTG contributes to the development of gliomas, by 
using two glioblastoma cell lines, U87 and LN229, whose growth and survival are dependent on 
tTG.  We show that tTG significantly enhances the signaling activity and lifetimes of EGF-
receptors (EGFRs) in these brain cancer cells.  Moreover, over-expressing tTG in T98G 
glioblastoma cells that normally express low levels of tTG, caused a marked up-regulation of 
EGFR expression and transforming activity.  We further show that tTG accentuates EGFR-
signaling by blocking c-Cbl-catalyzed EGFR ubiquitylation, through the ability of tTG to bind 
GTP and adopt a specific conformation that enables it to interact with c-Cbl.  These findings 
demonstrate that tTG contributes to gliomagenesis by interfering with EGFR down-regulation 
and thereby promoting transformation. 
 
Introduction 
Glioblastoma multiforme, also known as glioblastoma or grade IV astrocytoma, 
represents one of the most prevalent and aggressive forms of primary brain tumor that occurs in 
humans.  Glioblastomas are therapeutically challenging due to the collective effects of a number 
of traits frequently exhibited by these types of tumors including rapid growth rates, resistance to 
radiation and chemotherapy, a high recurrence rate following surgical resection, and an ability to 
*Previously published as Zhang J & Antonyak MA, et al. Cell Reports 2013 Jun 27;3(6):2008-20 
 

infiltrate surrounding normal tissue (1).  As a result, patients with glioblastomas tend to survive 
only 12-17 months following their initial diagnosis, even despite having received a multimodal 
therapy regiment (2).  Thus, there continues to be an over-riding need to develop additional 
strategies to manage this devastating form of cancer. 
In an effort to identify new potential targets for therapeutic intervention, we searched for 
proteins whose expression is up-regulated in glioblastoma and correlated with a poor patient 
prognosis.  One intriguing candidate that emerged is tTG, a GTP-binding protein/acyl transferase 
previously reported to be one of eleven metastasis-associated proteins selectively amplified in 
human lung and breast cancers (3, 4).  tTG promotes the growth and survival of several different 
cancer cell types (5, 6), outcomes that are largely thought to be dependent on its acyl transferase 
(protein crosslinking) activity.  In order to determine how tTG contributes to the development of 
malignant brain cancer, we used glioblastoma cell lines whose aberrant growth and survival are 
highly dependent upon tTG.  Here we show that tTG plays an important role in the transformed 
properties of these cancer cells by having a major influence on EGFR protein levels and 
signaling activities.  The ability of tTG to affect EGFR expression and function has significant 
implications for brain cancer given that this receptor tyrosine kinase has been shown to trigger 
mitogenic and survival responses in both normal astrocytes and brain tumor-derived cell lines(7, 
8).  Moreover, ectopic expression of the EGFR in normal cell types induces their transformation 
in a ligand-dependent manner, suggesting that increased signaling by the EGFR plays a critical 
role in promoting human malignancies (9). 
At the protein level, the EGFR is over-expressed in approximately 60-90% of all 
glioblastomas, with the extent of EGFR expression being correlated with poor patient outcomes 

 (10, 11).  Although amplification of the gene encoding the EGFR can account for the aberrant 
EGFR expression detected in 30-40% of primary brain tumors or brain tumor-derived cell lines 
(12, 13), additional mechanisms must be involved to account for the increased EGFR protein 
levels observed in those glioblastoma cases where gene amplification does not occur, as well as 
for the excessive and sustained EGFR-signaling that is characteristic of these brain cancers.  
Thus, it seemed likely that the disruption of the normal (negative) regulation of EGFRs 
contributes to the aberrant EGFR-signaling capabilities exhibited in at least some glioblastomas.  
Indeed, it is through the regulation of EGFR degradation where tTG appears to exert a major 
influence, because we show that it affects the ability of c-Cbl, an E3 ubiquitin ligase, to target the 
EGFR for lysosomal degradation.  This involves the ability of tTG, when bound to GTP and 
having adopted a specific GTP-induced conformational state, to associate with c-Cbl and block 
the c-Cbl-catalyzed ubiquitylation and degradation of EGFRs, thereby significantly enhancing 
and extending EGFR-signaling activities. 
 
Results 
tTG is over-expressed in human brain tumors 
tTG functions both as a GTPase and acyl transferase whose expression and activation 
have been shown to be up-regulated in several different types of human cancer including breast, 
ovarian, and pancreatic cancer (14-16).  In addition, tTG has been demonstrated to play an 
important role in the growth, survival, migration and invasive activity of aggressive cancer cells 
(17).  These findings, coupled with the fact that tTG was identified as a down-stream signaling 
partner of the EGFR, promoting the transformed characteristics of human breast cancer SKBR3 
cells (6), as well as having an essential function in the EGF-stimulated migration and invasion of 

 different cancer cells (18, 19), made it attractive to consider that tTG plays an important role in 
the development of brain cancer. 
We began by examining tTG expression levels in human primary brain tumors.  A tissue-
array consisting of normal brain tissues and astrocytomas ranging from grade I to grade IV 
(grade IV astrocytomas are also referred to as glioblastomas) was immuno-stained for tTG.  We 
found that, like the case for the normal human astrocyte (NHA) controls, tTG expression in 
normal brain is generally low (Figures 2.1A, 2.1B, and 2.1D, top panel).  Similarly, tTG is often 
expressed at relatively low levels in the lower grade (grades I and II) astrocytomas (Figure 2.1C, 
left panel).  However, in the more advanced/aggressive brain tumors (i.e. grades III and IV 
astrocytomas), tTG expression was frequently up-regulated. For example, greater than 80% of 
the grade III astrocytomas and nearly 60% of the grade IV astrocytomas showed increased tTG 
expression (Figure 2.1A).  Figure 2.1B shows a representative comparison of tTG expression in a 
normal brain sample versus a grade IV astrocytoma.  We then took our analysis one step further 
by comparing tTG transcript levels in the four sub-types of glioblastomas that have been 
identified according to their unique molecular signatures (20) using The Cancer Genome Atlas 
(TCGA).  Figure 2.1E shows that tTG transcript levels are increased in the mesenchymal (~45%) 
and classical (~16%) tumor sub-types.  
Overall, the trend we observed for tTG expression matched that for EGFR expression and 
phosphorylation (Figure 2.1C, middle and right panels).  While we were not able to draw a strict 
correlation between tTG expression and the survival of glioblastoma patients (Figure 2.1F, left 
panel), we did find a correlation based on tumor grade, similar to what has been observed for the 
EGFR (11, 21).  Individuals with gliomas of various grades whose tumors showed a 2-fold or 
greater increase in tTG expression had an ~25% reduction in their expected lifespan, whereas 

 
 
Figure 2.1.  tTG expression is up-regulated in high grade human brain tumors and 
correlates with poor patient outcomes. 
(A-C) Tissue arrays of human primary brain tumors of increasing grades and normal brain 
samples were subjected to immunohistochemical analysis using tTG, EGFR and phospho-EGFR 
antibodies. 
(A) Expression levels of tTG detected in the tissue array. Each symbol on the chart represents an 
individual normal brain or tumor sample as indicated. 
(B) Representative images of a normal brain sample and a grade IV tumor (glioblastoma) stained 
for tTG. Magnification is !10. 
(C) The expression levels of tTG (left) and the EGFR (middle), and the levels of EGFR 
phosphorylation (right) shown represent their enhanced expression in brain tumor tissue relative 
to their expression in normal brain tissue (which was set to 1). 
(D) Cell extracts from serum-starved normal human astrocytes (NHAs) and various brain tumor 
cell lines, were immunoblotted (IB) with tTG and actin antibodies (top two panels). The extracts 
were also assayed for their enzymatic transamidation activity, as read-out by the incorporation of 
BPA into lysate proteins (bottom panel). 
(E) The percentage of glioblastomas exhibiting increased tTG transcript levels was determined 
and then plotted by sub-type. 
(F) Kaplan-Meier Survival Plots for glioblastoma (GBM) patients (left panel) and all glioma 
patients (right panel) with differential tTG expression levels. Data cited from REMBRANDT, 
National Cancer Institute, accessed 2013, March 18. Downreg, downregulation; Upreg, 
upregulation. 
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 those individuals with a 2-fold or greater decrease in tTG expression benefited by an ~20% 
increase in their survival (Figure 2.1F, right panel).  
 
tTG is essential for the transformed properties of glioblastoma cell lines 
In order to learn more about the potential role played by tTG in brain cancer, we set out 
to identify human glioblastoma cell lines that exhibited tTG-dependent transformed phenotypes. 
Three commonly used human glioblastoma cell lines, U87, LN229, and T98G cells, were 
examined for tTG expression and acyl transferase activity.  As shown in Figure 2.1D, top panel, 
U87 and LN229 cells exhibited significantly higher levels of tTG expression compared to NHAs, 
while T98G cells exhibited only a modest increase in tTG levels.  The same was true when 
comparing the enzymatic transamidation activity catalyzed by tTG in lysates prepared from these 
different cell lines, as read-out by assaying the incorporation of biotinylated pentylamine (BPA) 
into their lysate proteins (Figure 2.1D, bottom panel) (22). 
We next asked whether the expression of tTG in these glioblastoma cells contributed to 
their ability to exhibit transformed phenotypes.  The anchorage-independent growth of U87, 
LN229, and T98G cells was assayed under conditions where tTG activity was blocked using two 
distinct tTG inhibitors, monodansyl cadaverine (MDC) and Z-Don, or after tTG expression was 
knocked-down by siRNA (Figures 2.2A and 2.2B). Figure 2.2C shows that the ability of both 
U87 and LN229 cells to form colonies in soft agar was sensitive to MDC and Z-Don, with the 
number of colonies formed by each of these cell lines being reduced by at least 60% upon 
treatment with the inhibitors. Likewise, the knock-down of tTG expression in U87 and LN229 
cells using two different siRNAs (Figure 2.2D, insets) inhibited colony formation (Figure 2.2D).  
In contrast, the anchorage-independent growth of T98G glioblastoma cells was not dependent on 

 
 
Figure 2.2.  tTG is essential for the transformed characteristics of U87 and LN229 
glioblastoma cells. 
(A) Cell extracts from serum-starved U87, LN229 and T98G cells treated without or with MDC 
or Z-Don for 1 day were immunoblotted (IB) with tTG and actin antibodies (bottom two panels), 
as well as assayed for their enzymatic transamidation activity (top panel). 
(B) Cell extracts from U87, LN229 and T98G cells expressing control or tTG siRNAs were 
immunoblotted (IB) with tTG and actin antibodies (bottom two panels), or assayed for their 
enzymatic transamidation activity (top panel). 
(C) Soft agar colony formation assays were performed on U87, LN229 and T98G cells treated 
without or with MDC or Z-Don. After 10 days of growth, the colonies that formed were counted. 
(D) U87, LN229, and T98G cells transfected with control or tTG siRNAs were either lysed and 
immunoblotted (IB) with tTG and actin antibodies (insets), or subjected to soft agar colony 
formation assays. After 10 days of growth, the colonies that formed were counted. 
(E) Apoptotic assays were performed on U87, LN229 and T98G cells cultured in serum-free 
medium supplemented without or with MDC, and without or with doxorubicin (Dox), for 1 day. 
Apoptotic cells were identified by the presence of condensed or blebbed nuclei.  
(C-E) Data are represented as mean ± SEM. 
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 tTG, as it was insensitive to tTG inhibitors MDC and Z-Don, as well as to siRNAs targeting tTG 
(Figures 2.2C and 2.2D). 
It was previously shown that these brain cancer cells are resistant to chemotherapy (23-
25), and indeed challenging the different glioblastoma cell lines with doses of doxorubicin that 
potently killed other types of human cancer cells (i.e. SKBR3 breast cancer cells) (22), induced 
only modest increases in cell death beyond that normally observed in the absence of any 
treatment (Figure 2.2E).  When assaying the survival of these glioblastoma cell lines following 
their exposure to various combinations of MDC and doxorubicin, we found that MDC treatment 
alone caused little or no increase in their rates of apoptosis (Figure 2.2E).  However, when the 
cells were treated with both MDC and doxorubicin, an ~2-3 fold increase in apoptosis occurred 
in U87 and LN229 cells compared to what was observed with doxorubicin alone (Figure 2.2E, 
left and middle panels), whereas, treatment of T98G cells with the combination of MDC and 
doxorubicin showed essentially no effect (Figure 2.2E, right panel).  Together, these findings 
demonstrate that the over-expression of tTG that occurs in highly aggressive human brain tumors 
and glioblastoma cell lines (U87 and LN229) strongly contributes to their aberrant growth and 
chemo-resistance. 
 
tTG regulates EGFR levels and the extent of EGFR-signaling activities in brain tumor cells 
Both tTG and EGFR expression levels are frequently up-regulated in high grade brain 
tumors.  Thus, we examined whether EGFR-signaling might be enhanced and/or extended in a 
glioblastoma cell line that showed relatively high tTG expression and whose transformed 
properties were dependent upon tTG (U87 cells), compared to a cell line that expressed relatively 
low levels of tTG and was not dependent upon it for transformation (T98G cells).  Indeed, we 

 found that the signaling lifetimes of activated EGFRs in U87 cells were extended, compared to 
the case for T98G cells (Figure 2.3A). This appeared to be preceded by a significantly greater 
extent of EGFR ubiquitylation in T98G cells compared to U87 cells (Figure 2.3B). 
We then set out to establish that tTG is responsible for enhancing EGFR-signaling in 
glioblastoma.  First, we took advantage of the fact that T98G glioblastoma cells have relatively 
low levels of tTG expression and are not dependent upon tTG for their survival or transformed 
growth properties.  Interestingly, these brain cancer cells also showed virtually no dependence on 
EGFR-signaling for their transformed characteristics, as indicated by their insensitivity to the 
EGFR tyrosine kinase inhibitor AG1487 (Figure 2.3C, compare the first and second histograms).  
We then generated T98G cells that stably expressed either vector-alone or a Myc-tagged form of 
tTG (Figure 2.3D, top two panels). As expected, lysates from the cells over-expressing Myc-
tagged tTG exhibited significantly more transamidation activity than lysates from cells 
expressing vector-alone (Figure 2.3D, bottom panel).  While T98G cells that expressed just the 
vector-alone were capable of forming colonies in soft agar, cells that ectopically expressed tTG 
showed a significant increase (i.e. ~2-fold) in their anchorage-independent growth (Figure 2.3C, 
compare the first and third bars).  Moreover, upon ectopically expressing tTG in T98G cells, the 
EGFR protein levels increased by 3- to 4-fold (Figure 2.3E, top panel, compare the first and third 
lanes).  This increase in EGFR levels was off-set upon treatment of the cells with the tTG 
inhibitor MDC (Figure 2.3E, compare the third and fourth lanes), thereby directly demonstrating 
that tTG influences EGFR expression.  We then asked whether the ability of tTG to potentiate 
EGFR levels in T98G transfectants was important for the enhanced transforming capabilities 
exhibited by the T98G cells stably over-expressing tTG.  As shown in Figure 2.3C, the enhanced 
colony formation exhibited by T98G cells upon the ectopic expression of tTG was nearly 

 
 
Figure 2.3.  EGFR signaling is potentiated in U87 glioblastoma cells. 
(A) Extracts from U87 and T98G cells that had been cultured in serum-free medium and then 
further stimulated without or with EGF for increasing lengths of time, were immunoblotted (IB) 
using a phospho-EGFR antibody (insets). The relative activity of the EGFR in each cell line was 
plotted (the EGFR activity detected at 10 min of EGF stimulation was set as the maximal activity 
for each cell line). 
(B) Immunoprecipitations with an EGFR antibody (IP: EGFR) were performed on the extracts 
from U87 and T98G cells that had been cultured in serum-free medium and then further 
stimulated without or with EGF for 10 min. The resulting immuno-complexes were 
immunoblotted (IB) with EGFR and ubiquitin antibodies, and the relative ubiquitylation levels of 
the EGFR for each sample were plotted (the level of EGFR ubiquitylation detected in U87 cells 
stimulated with EGF for 10 min was set as 1). 
(C) Soft agar colony formation assays were performed on the T98G stable cell lines treated 
without or with AG1478. 
(A-C) Data are represented as mean ± SEM. 
(D) Extracts from T98G cells stably expressing the vector-alone or a Myc-tagged wild-type tTG 
(tTG WT) were immunoblotted (IB) with Myc, tTG, and actin antibodies (top three panels), as 
well as assayed for their enzymatic transamidation activity, as read-out by the incorporation of 
BPA into lysate proteins (bottom panel). 
(E) Extracts from the T98G stable cell lines cultured in serum-free medium supplemented 
without or with MDC were immunoblotted (IB) with EGFR, tTG and actin antibodies. 
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 completely eliminated by AG1478 (compare the third and fourth histograms), indicating that the 
enhancement in transformation accompanying over-expression of tTG was dependent upon 
EGFR tyrosine kinase activity. 
We then made use of the U87 and LN229 glioblastoma cell lines to further establish that 
tTG mediates the up-regulation of EGFR expression and signaling.  Figure 2.4A (top two panels) 
shows that treatment of both U87 and LN229 cells with the tTG inhibitor MDC consistently 
reduced the basal levels of EGFR expression and activation, as read-out using an anti-pan-EGFR 
antibody and an anti-phospho-EGFR antibody that detects EGFR auto-phosphorylation, 
respectively. Likewise, MDC treatment markedly reduced the amount of EGFR-stimulated 
phosphorylation of c-Jun, ERK and Akt in both cell lines (Figure 2.4A, third, fifth and seventh 
panels), signaling outcomes occurring downstream from the EGFR that are frequently observed 
in primary brain tumors and brain tumor-derived cell lines, including U87 cells (Figure 2.4B) 
(26-28).  To further confirm a role for tTG in regulating EGFR expression levels, we examined 
whether a decrease in the cellular steady-state levels of the EGFR accompanied siRNA-mediated 
knock-downs of tTG.  Indeed, the siRNA-induced reduction in tTG levels by ~80% in U87 cells 
and ~50% in LN229 cells (Figure 2.4C, second panels from the top), resulted in corresponding 
decreases in EGFR expression (Figure 2.4C, top panels). 
We next examined whether tTG influenced the extent of EGFR-signaling activities in 
these glioblastoma cells.  Serum-starved cultures of U87 cells were treated with EGF for 
increasing lengths of time, in the presence or absence of MDC.  Figure 2.4D shows that a 
maximal activation of EGFR tyrosine kinase activity occurred within 10 minutes of growth 
factor treatment (top panel). EGF stimulation of U87 cells pretreated with MDC showed a 
marked reduction in the magnitude of EGFR activation.  Cell surface biotin-labeling experiments 

 
 
Figure 2.4.  tTG regulates EGFR levels and signaling activity in glioblastoma cells. 
(A) Extracts from U87 and LN229 cells cultured in serum-free medium supplemented without or 
with MDC for 1 day were immunoblotted (IB) using the indicated antibodies. The fold changes 
in EGFR levels, as determined using ImageJ, are highlighted. 
(B) The basal c-Jun, ERK and Akt activities in U87 cells are dependent on the EGFR. Cell 
extracts from serum-starved U87 cells treated without or with AG1478 for 1 day were 
immunoblotted (IB) using phospho-specific EGFR, c-Jun, ERK and Akt antibodies, as well as 
with tTG and actin antibodies. 
(C) Extracts from U87 cells and LN229 cells expressing control or tTG siRNAs were 
immunoblotted (IB) using EGFR, tTG, and actin antibodies. The fold changes in EGFR levels, as 
determined using ImageJ, are highlighted. 
(D) Extracts from U87 cells that had been cultured in serum-free medium and then treated 
without or with MDC for 30 min before being further stimulated with EGF for increasing lengths 
of time, were immunoblotted (IB) using the indicated antibodies. 
(E) U87 cells treated without or with MDC for 1 day were incubated with a cell impermeable 
biotinylation reagent to label surface proteins and then lysed. Immunoprecipitations with an 
EGFR antibody (IP: EGFR) were performed on the cell extracts. The resulting immuno-
complexes were first blotted with Streptavidin-HRP to detect the amount of cell surface EGFR 
and then were re-probed with an EGFR antibody to confirm that the EGFR was 
immunoprecipitated. A small sample of the cell extracts (WCLs) was also immunoblotted with 
the indicated antibodies. 
(F) EGF-stimulated activation of the EGFR in LN229 glioblastoma cells is attenuated by MDC 
treatment.  Cell extracts from LN229 cells that had been cultured in serum-free medium and then 
were treated without or with MDC for 30 minutes before being further stimulated with EGF for 
the indicated lengths of time, were immunoblotted (IB) using the phospho-EGFR, as well as with 
tTG and actin antibodies. 
(G) EGFRvIII expression levels are not influenced by tTG. U87 cells stably expressing either the 
vector-alone or EGFRvIII were cultured in serum free medium with or without MDC for 1 day 
before being lysed. The cell extracts were then immunoblotted with EGFR, tTG and actin 
antibodies. Note that MDC treatment reduces the levels of the endogenous wild-type EGFR, but 
not that of the ectopically expressed EGFRvIII. 
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 performed on the cells showed that this was due to reductions in the EGFR levels at the plasma 
membrane (Figure 2.4E). Moreover, the phosphorylation of c-Jun (Figure 2.4D, second panel 
from the top) and ERK (Figure 2.4D, third panel from the top) was significantly reduced in U87 
cells pretreated with MDC.  While each of these signaling events showed little dependence on 
EGF stimulation, the basal activities of both were dependent on EGFR activity as indicated by 
the inhibition caused by the specific EGFR tyrosine kinase inhibitor AG1478 (Figure 2.4B). 
EGFR activation was also compromised in LN229 glioblastoma cells treated with the tTG 
inhibitor MDC (Figure 2.4F).   
We also examined whether tTG could influence the levels of the EGFR variant type III 
(EGFRvIII), a commonly occurring and highly oncogenic mutant form of the EGFR that is 
defective in its down-regulation (29). Figure 2.4G shows that ectopic EGFRvIII expression in 
U87 cells was not affected by MDC treatment (compare the first and second lanes to the third 
and fourth lanes). This suggests that tTG is not important for extending the lifetime of this 
mutant EGFR, most likely because unlike the wild-type EGFR, this truncated EGFR variant has 
an inherent insensitivity to the degradative actions of c-Cbl (30) (also see below).  
 
tTG blocks ubiquitylation of the EGFR  
Taken together, the results presented in Figures 2.3 and 2.4, as well as those shown in 
Figure 2.5A, left panel, suggest that the actions of tTG are directed at enhancing the stability of 
wild-type EGFRs. The ubiquitylation-mediated down-regulation of the EGFR, as catalyzed by 
the E3 ubiquitin ligase c-Cbl, plays an essential role in terminating EGFR-signaling activities by 
targeting the receptor for degradation in the lysosomes (31, 32).  Figure 2.5A, right panel, shows 
that following treatment of U87 cells with MDC or Z-Don, the amount of detectable 
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Figure 2.5.  tTG influences the ubiquitylation of the EGFR by associating with E3 ubiquitin 
ligase c-Cbl. 
(A) Immunoprecipitations with an EGFR antibody (IP:EGFR) were performed on the extracts 
from U87 cells that were cultured in serum-free medium supplemented without or with MDC or 
Z-Don for 1 day. The resulting immuno-complexes as well as samples of the whole cell lysates 
(WCLs) were immunoblotted (IB) with EGFR, ubiquitin, tTG and actin antibodies. 
(B) Cell extracts from U87 cells treated without or with MDC or Z-Don for 1 day were 
immunoblotted (IB) with ubiquitin and actin antibodies. 
(C) Immunoprecipitations with an EGFR antibody (IP: EGFR) were performed on the extracts 
from U87 cells expressing control or tTG siRNAs. The resulting immuno-complexes were then 
immunoblotted (IB) with EGFR and ubiquitin antibodies. The fold changes in ubiquitinylated 
EGFR, as determined using ImageJ, are highlighted. 
(D) Immunoprecipitations with an EGFR antibody (IP: EGFR) were performed on the extracts 
from LN229 cells cultured in serum-free medium supplemented without or with MDC, for 1 day. 
The resulting immuno-complexes were then immunoblotted (IB) with EGFR and ubiquitin 
antibodies. 
(E) Immunoprecipitations with an HA antibody (IP: HA-c-Cbl) were performed on extracts from 
U87 cells transfected with HA-tagged c-Cbl (HA-c-Cbl) and cultured in serum-free medium 
supplemented without or with MDC for 1 day. The resulting immuno-complexes, as well as the 
whole cell extracts collected (WCLs), were immunoblotted (IB) with tTG and HA antibodies. 
(F) List of the various tTG constructs used in this study including: the name of each construct, 
the sites of the mutations, and their functional consequences on nucleotide binding and 
enzymatic transamidation activity are indicated. 
(G) Immunoprecipitations with an HA antibody (IP: HA-c-Cbl) were performed on extracts from 
U87 cells transfected with HA-tagged c-Cbl and either Myc-tagged wild-type tTG (Myc-tTG 
WT) or one of the indicated Myc-tagged mutant forms of tTG listed in D.  The resulting 
immuno-complexes, as well as the whole cell extracts collected (WCLs), were immunoblotted 
(IB) with HA, Myc, and actin antibodies. 
(H) Purified, recombinant His-tagged, wild-type (WT) tTG, or one of the mutant forms of tTG, 
were incubated alone or together with an equal amount of recombinant GST-tagged c-Cbl. The 
resulting protein complexes were precipitated with GST beads and then immunoblotted with tTG 
and c-Cbl antibodies (Pull-down: GST). Each form of His-tagged tTG used in the pull-down 
assay was also immunoblotted with a tTG antibody to confirm that equal amounts of 
recombinant tTG were used in the experiment (Input). 
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 ubiquitylation of the immunoprecipitated EGFR was enhanced, compared to an equivalent 
amount of EGFR immunoprecipitated from untreated cells.  It is worth noting that the overall 
levels of ubiquitylated proteins in U87 cells were largely unaffected by MDC or Z-Don treatment 
(Figure 2.5B), suggesting that the changes in the ubiquitylation status of the EGFR caused by 
tTG represented a specific regulatory event.  Similar increases in EGFR ubiquitylation were 
observed when tTG expression was knocked-down by siRNAs in U87 cells (Figure 2.5C), or 
when LN229 cells were exposed to MDC (Figure 2.5D). 
In an effort to understand the molecular mechanism by which tTG inhibits EGFR 
ubiquitylation, we examined whether tTG might be capable of associating with c-Cbl in cells.  
Figure 2.5E shows that endogenous tTG can be co-immunoprecipitated with HA-tagged c-Cbl 
from U87 cells.  This interaction was greatly reduced when the cells were treated with MDC.  
Based on these findings, our initial assumption was that the acyl transferase or transamidation 
activity of tTG was in some way involved in its ablity to associate with and/or negatively 
regulate the function of c-Cbl.  Such an idea was consistent with several findings that suggested 
the enzymatic transamidation activity of tTG was necessary for mediating many of its effects in 
cells (16, 22, 33). 
We therefore set out to further examine this possibility by using various tTG mutants that 
we have developed in the laboratory (Figure 2.5F).  The results in Figure 2.5G (panels on the 
right) show that a Myc-tagged wild-type tTG construct was capable of associating with HA-
tagged c-Cbl, similar to what we had observed with endogenous tTG, whereas, a transamidation-
defective mutant, tTG C277V, in which the active site cysteine residue had been changed to a 
valine (6), was incapable of being co-immunoprecipitated with c-Cbl.  This seemed to support 
the suggestion that the transamidation activity of tTG was involved in the interaction.  However, 
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 surprisingly, we found that another tTG mutant, tTG D306N, N310A (referred to as the “Site-II 
mutant”), that was incapable of catalyzing transamidation because of two substitutions at one of 
the major Ca2+-binding sites essential for catalysis (33), was able to associate with c-Cbl (Figure 
2.5G, panels on the right).  Moreover, a GTP-binding-defective tTG mutant (tTG R580K), that 
exhibits greatly enhanced transamidation activity because its enzymatic activity is not subject to 
the same negative regulation that accompanies the binding of GTP to wild-type tTG (34), was 
incapable of associating with c-Cbl.  Collectively, these results ruled out the possibility that the 
transamidation activity of tTG was required for its ability to associate with and inhibit the E3 
ubiquitin ligase activity of c-Cbl. 
We then asked whether the ability of tTG to associate with c-Cbl in cells was the 
outcome of a direct binding interaction.  Purified recombinant, His-tagged wild-type tTG, as well 
as different tTG mutants, were incubated with purified recombinant GST-c-Cbl, and then the 
proteins were examined for complex formation by precipitating the GST-c-Cbl with glutathione-
coated agarose beads.  Figure 2.5H (first lane) shows that His-tagged wild-type tTG was co-
precipitated with GST-c-Cbl, indicating that these proteins undergo a direct binding interaction.  
Likewise, the recombinant His-tagged tTG Site-II mutant was able to bind GST-c-Cbl, whereas 
His-tagged tTG R580K and His-tagged tTG C277V were ineffective (Figure 2.5H), consistent 
with our co-immunoprecipitation data in cells. 
 
The GTP-bound ‘closed’ form of tTG is responsible for inhibiting c-Cbl function 
We next examined whether the GTP-binding activity of tTG is involved in its ability to 
associate with c-Cbl. The GTP-binding capabilities of the different tTG mutants, relative to the 
wild-type protein, were assayed by taking advantage of the ability of the fluorescent GTP-

 analog, BODIPY-GTP, to rapidly bind tTG and undergo a significant change in its fluorescence 
emission (34). Figure 2.6A shows that, like the case for wild-type tTG (top left panel), BODIPY-
GTP was capable of rapidly associating with the tTG Site-II mutant  (top right panel), with the 
binding being sustained until the addition of unlabeled GTP!S, which caused a rapid reversal of 
the interaction with the labeled GTP-analog.  BODIPY-GTP also showed a rapid association 
with the tTG C277V mutant (Figure 2.6A, bottom left panel); however, this was followed by a 
steady dissociation of the labeled GTP-analog, indicative of a much weaker interaction compared 
to either wild-type tTG or the tTG Site-II mutant.  The tTG R580K mutant showed essentially no 
ability to bind BODIPY-GTP (Figure 2.6A, bottom right panel), consistent with our earlier 
studies that showed this mutant to be GTP-binding-defective (34).  
X-ray crystallographic studies have shown that tTG can exist in two distinct 
conformational states.  When bound to guanine nucleotide (i.e. GTP-bound in cells), tTG adopts 
what is referred to as a ‘closed’ conformational state where the "1 and "2 barrel domains fold 
over the central core of the protein that contains the transamidation catalytic site (35) (Figure 
2.6B, left side).  However, in the absence of bound GTP, the protein assumes a more extended or 
‘open’ conformation in which the catalytic site is fully accessible (Figure 2.6B, right side).  This 
was first shown when the x-ray structure was solved for tTG bound to a peptide that mimics the 
inflammatory gluten peptide substrate that binds to the transamidation active site (36).  Thus, 
when the structural data is taken together with the results of the co-immunoprecipitation and 
GST pull-down experiments presented in Figures 2.5G and 2.5H, as well as the GTP-binding 
data in Figure 2.6A, it would appear that it is the GTP-bound, closed state of tTG that is best 
suited for associating with and functionally inactivating c-Cbl. 
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Figure 2.6.  tTG adopts distinct conformations depending on whether it is bound to GTP. 
(A) Purified recombinant forms of wild-type tTG (tTG WT), tTG C227V, tTG R580K, and the 
tTG Site-II mutant were incubated with BODIPY-GTP and the resulting changes in fluorescence 
caused by the binding of BODIPY-GTP to the proteins were determined. * indicates the point in 
the assay when an excess of unlabeled GTP!S was added to the tTG proteins to compete off 
BODIPY-GTP. 
(B) X-ray crystal structures and schematic representations of the closed and open conformations 
of tTG.  tTG adopts a closed conformation when it is bound to GDP (PDB: 1KV3) (left side), or 
an open conformation when it is in a nucleotide free state (PDB: 2Q3Z). The domains 
highlighted in the tTG diagrams include the N-terminal " sandwich (N), the catalytic core (core), 
and the two C-terminal "-barrels ("1 and "2). 
(C) Purified recombinant forms of wild-type tTG (tTG WT), tTG C277V, tTG R580K, tTG Site-
II (3.0 !g of each protein) were incubated without or with trypsin for 2 hours before being 
resolved by SDS-PAGE and then stained with Coomassie blue to visualize the proteins. 
(D) Purified recombinant wild-type tTG (3.0 !g) pre-treated without or with increasing amounts 
of MDC was incubated with trypsin for 2 hours before being resolved by SDS-PAGE and then 
stained with Coomassie blue to visualize the proteins. 
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 Further support for this idea came from studies where we examined the protease-
sensitivity of wild-type tTG and the different tTG mutants.  Figure 2.6C shows that wild-type 
tTG, and the tTG Site-II mutant, exhibited similar capabilities for resisting trypsin proteolysis, 
whereas, the tTG C277V mutant behaved in a similar manner to the GTP-binding-defective tTG 
R580K mutant and was highly sensitive to protease treatment. This indicates that the tTG Site-II 
mutant adopts an overall conformation similar to that of the GTP-bound, wild-type protein, as 
indicated by its ability to resist trypsin proteolysis, whereas the tTG C277V mutant assumes a 
conformation more like that of the GTP-binding-defective tTG R580K mutant.  Interestingly, we 
found that MDC, in a dose-dependent manner, enhanced the protease sensitivity of wild-type 
tTG, thus causing it to behave more like the tTG R580K and tTG C277V mutants (Figure 2.6D).  
These findings might then explain why MDC treatment inhibits the ability of tTG to interact with 
c-Cbl, as read-out in co-immunoprecipitation experiments (Figure 2.5E).  Specifically, rather 
than weakening the interaction between tTG and c-Cbl by blocking access to the transamidation 
active site of tTG, the binding of the inhibitor helps tTG to assume a more open conformation 
that has very weak affinity for c-Cbl. 
The relative effectiveness of these different mutants to associate with c-Cbl could be 
correlated with their effects on EGFR activation (auto-phosphorylation) and receptor 
ubiquitylation.  Figure 2.7A shows that when the different mutants were transiently expressed in 
U87 cells as Myc-tagged proteins, both wild-type tTG and the Myc-tTG Site-II mutant were able 
to increase the levels of activated EGFR upon EGF treatment, whereas the Myc-tTG C277V 
mutant and the GTP-binding-defective Myc-tTG R580K mutant were completely ineffective.  
Although we were not able to make reliable comparisons of the effects of the different mutants 
on EGFR ubiquitylation in U87 cells, we were able to compare their actions in the human breast 
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Figure 2.7.  Ectopic expression of tTG forms that are in the “closed” conformation 
enhances EGFR signaling. 
(A) Cell extracts from U87 cells ectopically expressing the vector-alone, wild-type tTG (Myc-
tTG WT), or one of the different mutant forms of tTG stimulated without or with EGF (100 
ng/ml) for 20 min, were immunoblotted (IB) using phospho-EGFR, Myc, and actin antibodies. 
(B) Immunoprecipitations with an EGFR antibody (IP: EGFR) were performed on the cell 
extracts from SKBR3 cells transfected with wild-type (Myc-tTG WT) or one of the different 
mutant forms of tTG indicated. The resulting immuno-complexes were then immunoblotted (IB) 
with ubiquitin and EGFR antibodies. 
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 cancer cell line, SKBR3, which lacks endogenous tTG expression. The results of these 
experiments suggested that only wild-type tTG and the tTG Site-II mutant were able to reduce 
EGFR ubiquitylation (Figure 2.7B), which was fully consistent with their abilities to associate 
with c-Cbl. 
 
Discussion 
In this study, we set out to gain new insights into the molecular mechanisms contributing 
to the development of malignant gliomas.  These efforts led us to tTG, a GTP-binding protein 
and Ca2+-dependent acyl transferase, whose expression is up-regulated in several types of cancer 
(6, 14, 16).  We show that this is also true for malignant gliomas. While the levels of tTG were 
consistently low in normal brain, as well as in most grade I and II tumors, tTG expression was 
noticeably up-regulated in the more aggressive, high grade (i.e. grades III and IV) tumors.  In 
fact, we found that it was over-expressed in ~70% of these cases, making the up-regulation of 
tTG expression one of the most frequently occurring events in human brain tumors.  Moreover, 
there appears to be a correlation between the increased expression of tTG in brain cancer and a 
poor survival prognosis for patients. 
A number of studies have implicated tTG in cancer cell growth, chemoresistance, 
invasiveness, and metastasis (16, 17), and to be a downstream signaling partner of the EGFR (6, 
18, 19).  Its involvement in EGFR-signaling was particularly intriguing to us, since EGFR over-
expression and activating EGFR mutations are recurring themes in human cancer and are 
especially important for the aggressive phenotypes exhibited by high grade primary brain tumors 
(29, 37, 38). In fact, over-expression of the EGFR has been reported in a large majority of the 
high grade (grade IV) tumors or glioblastomas, while it is rarely seen in the lower grade I and II 
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 brain tumors.  Consequently, EGFR status is considered to be a prognostic indicator for patients 
with brain tumors (10, 21, 39). 
It has been well established that the amplification of the gene encoding the EGFR 
represents one common mechanism through which EGFR expression levels are increased in 
glioblastomas (38).  However, 10-30% of brain cancers that show high EGFR expression contain 
a normal receptor gene copy number. Therefore, additional mechanisms must account for the 
relatively high EGFR protein levels and enhanced EGFR-signaling observed in some brain 
cancers (29).  In light of these findings, we began to consider the idea that a previously 
unappreciated functional interplay might exist among tTG, the EGFR, and brain tumor 
progression. This in fact turned out to be the case. We now describe how tTG helps maintain 
EGFR protein levels in glioblastomas, enhancing the extent and lifetime of EGFR activation and 
down-stream signaling activities, through a mechanism that does not involve gene amplification 
but, rather, is due to the ability of tTG to interfere with receptor ubiquitylation and degradation 
that is normally catalyzed by the EGFR-adaptor protein and negative regulator, c-Cbl.  
Work by Vivanco et al. showed that PTEN loss can result in a diminished c-Cbl-
dependent degradation of EGFRs (40).  Because previous studies from our laboratory showed 
that the PI3K/Akt pathway is necessary for the up-regulation of tTG expression in breast cancer 
cells upon growth factor treatment (6), we asked whether the inactivation of PTEN could 
regulate tTG levels and that perhaps changes in tTG expression could explain the effects of 
PTEN on EGFR degradation. Consistent with previous reports, U87 cells contain a truncated 
version of PTEN, LN229 cells express wild-type PTEN, and T98G cells contain PTEN harboring 
a point mutation (41). However, although an inverse correlation appears to exist between the 
expression levels of tTG and PTEN in the different glioblastoma cells that we examined (Figure 
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Figure 2.8.  tTG expression is not regulated by PTEN.  
(A) Cell extracts from U87, LN229, and T98G cells were immunoblotted (IB) with tTG, PTEN, 
phospho-PTEN, and actin antibodies. 
(B) Cell extracts from U87 cells transiently expressing increasing amounts of HA-tagged PTEN 
for two days were immunoblotted with tTG, HA, and actin antibodies.  
(C) Cell extracts from serum-starved U87, LN229 and T98G cells treated without or with 
LY294002 for 3 days were immunoblotted with tTG and actin antibodies. 
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 2.8A), we did not observe any significant change in the levels of tTG when we ectopically 
expressed increasing amounts of PTEN in U87 cells (Figure 2.8B) or mimicked PTEN function 
by inhibiting downstream signaling events with a PI3K inhibitor LY294002 (Figure 2.8C), 
suggesting that up-regulation of tTG in these brain cancer cells is not due to inactivation of 
PTEN. 
tTG is best known for its enzymatic, Ca2+-dependent acyl transferase activity that 
catalyzes the crosslinking of proteins through the formation of covalent linkages between 
glutamine residues on ‘acceptor’ proteins and lysine residues on ‘donor’ proteins (17).  However, 
interestingly, tTG is also capable of binding and hydrolyzing GTP similar to other classical G-
proteins (17).  These two activities are reciprocally regulated, such that GTP-bound tTG exhibits 
little detectable transamidation activity, whereas millimolar levels of Ca2+ weaken GTP binding 
to tTG and thereby stimulate its enzymatic activity.  This would imply that intracellular tTG 
exists in its GTP-bound state, given the high cellular concentrations of GTP and typically low 
concentrations of Ca2+, whereas upon its secretion, tTG may then be capable of catalyzing 
protein crosslinking events.  In fact, as schematized in Figure 2.9 and discussed further below, 
our data suggest it is the GTP-bound, closed state of tTG that is responsible for preventing c-Cbl 
from exerting its negative regulatory effects on the EGFR. 
Two key findings have provided us with a mechanistic picture of how tTG blocks the 
actions of c-Cbl and thereby helps maintain EGFR protein levels in glioblastoma cells.  U87 and 
LN229 human glioblastoma cell lines are highly dependent on EGFR-signaling for their 
transformed phenotypes. Interestingly, these cell lines also express inordinately high levels of 
tTG.  Moreover, when tTG expression was knocked-down in these cells by siRNA, 
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Figure 2.9.  Schematic representation depicting the effects of tTG on EGFR signaling.  In 
normal conditions, c-Cbl is recruited to the activated EGFR and mediates its ubiquitylation.  The 
ubiquitylated EGFR is then endocytosed and targeted for degradation in the lysosome. In brain 
tumor cells where tTG is abundantly expressed, tTG forms a complex with c-Cbl and prevents it 
from ubiquitylating the EGFR.  This disrupts the normal down-regulation of the EGFR, 
extending its signaling lifetime and enhancing cellular transformation. 

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 corresponding reductions were observed in the expression and activation of the EGFR, as well as 
in the transforming capabilities of these cancer cell lines. 
Perhaps even more striking were the results from experiments that took advantage of the 
unique qualities of the T98G glioblastoma cell line.  Unlike U87 and LN229 cells, T98G cells 
are not dependent on the EGFR for their transforming potential.  Moreover, they do not express, 
nor are they dependent upon, tTG for their transformed properties.  However, when a Myc-
tagged form of tTG was stably introduced into these cells, EGFR expression was increased 
between 3- and 4-fold compared to the vector-alone expressing control cells.  Importantly, T98G 
cells over-expressing tTG were capable of forming nearly twice as many colonies in soft agar as 
their control counterparts, an outcome that was dependent on the enhanced EGFR activity 
associated with these cells.  Thus, these findings demonstrate that the over-expression of tTG in 
at least certain brain tumor cell lines is sufficient to maintain relatively high EGFR levels and 
exacerbate their transformed phenotypes.  Since tTG is overexpressed in several additional types 
of human cancer (i.e. breast, ovarian, and pancreatic cancer), it will be interesting to see whether 
this interplay between tTG and the EGFR holds up in these cancer types as well. 
How does tTG have such profound effects on the actions of c-Cbl, and consequently, 
EGFR expression in glioblastomas?  Given that knock-downs of tTG expression in U87 and 
LN229 cells, as well as the treatment of these cells with the tTG crosslinking inhibitor MDC or 
Z-Don, markedly increased the amounts of ubiquitylated EGFRs, we had initially assumed that 
the transamidation activity of tTG was responsible for its ability to inactivate the E3 ubiquitin 
ligase activity of c-Cbl.  However, a careful analysis of the interaction of tTG with c-Cbl 
revealed that it did not rely upon, and indeed occurred independently of, tTG’s transamidation 
activity, but instead appeared to be dependent on its GTP-binding capability.  This is especially 
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 interesting in light of structural studies that show the binding of GTP to tTG causes the protein to 
adopt a ‘closed conformation’ that maintains it in an enzymatically-inactive state by blocking 
substrate access to the catalytic domain.  Under conditions of high Ca2+ (as might occur when 
tTG is extracellular), GTP dissociates, and tTG adopts an ‘open conformation’, in which the 
transamidation active site is accessible and able to catalyze the crosslinking of proteins. Thus, the 
only mutant form of tTG that constitutively adopts the closed state (i.e. Site-II mutant) is capable 
of binding to c-Cbl and blocking its ability to catalyze EGFR ubiquitylation.  The ability of 
MDC treatment to block tTG from protecting the EGFR from c-Cbl-mediated ubiquitylation is 
most likely an outcome of this competitive tTG inhibitor causing the protein to adopt an open 
conformation which has weak affinity for c-Cbl. Similarly, the x-ray structure for Z-Don 
covalently linked to the active site cysteine of tTG (PDB accession # 3S3J) shows that the 
inhibitor-tTG complex adopts an open conformation, consistent with the ability of Z-Don to 
block the protective effects of tTG. Therefore, we believe that it is the GTP-bound, closed state 
of tTG, perhaps acting in a manner analogous to classical signaling G-proteins, that enables it to 
associate with c-Cbl and thereby provides a unique mode of regulation of EGFR expression 
(Figure 2.9). 
In closing, we have identified a novel mechanism where through the actions of tTG, 
relatively high EGFR protein levels can be maintained, and EGFR-signaling activities enhanced 
and extended in human brain tumors, thus contributing to their oncogenic phenotypes.  Given 
that a number of therapeutic strategies directed at blocking EGFR activation and function, 
primarily through the use of tyrosine kinase inhibitors and monoclonal antibodies, have only had 
limited success in the clinics, there remains an over-riding need to develop novel approaches that 
target the EGFR.  Our finding that tTG is frequently over-expressed in high grade brain tumors, 

 coupled with the fact that it interferes with the proper down-regulation of the EGFR, raises the 
interesting possibility that developing approaches that block the ability of tTG to interact with c-
Cbl may offer potentially new strategies for therapeutic intervention. 
 
Experimental Procedures 
Materials 
Cell-culture reagents, EGF, Lipofectamine, Lipofectamine 2000, Protein-G agarose beads, and 
the control and tTG siRNAs were obtained from Invitrogen. G418, MDC, AG1478, and 
doxorubicin were from Calbiochem. Z-Don was from Zedira and BPA was from Pierce. 
Antibodies for tTG and actin were purchased from Thermo Fisher Scientific. Antibodies for 
EGFR, phospho-EGFR, phospho-Akt, Akt, phospho-c-Jun, c-Jun, phospho-ERK, ERK, PTEN 
and phospho-PTEN were from Cell Signaling. Ubiquitin and c-Cbl antibodies were from Santa 
Cruz, and HA and Myc antibodies were from Covance. Avidin/Biotin blocking solutions, Elite 
ABC reagent, and chromogen solution for immunohistochemical analysis were obtained from 
Vector Labs. 
 
Cell culture, transfections, inhibitor treatments 
U87 and SKBR3 cells were maintained in RPMI 1640 medium supplemented with 10% fetal 
bovine serum (FBS), the LN229 and T98G cells were maintained in DMEM supplemented with 
10% FBS, while NHAs were maintained in AGM (Lonza) supplemented with the BulletKit 
(Lonza). The expression constructs were introduced into cells using Lipofectamine, while the 
control and tTG siRNAs were introduced into cells using Lipofectamine 2000.  T98G cells stably 
expressing the vector-alone or Myc-tagged tTG were selected by supplementing the growth 
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 medium with 1 mg/ml G418. Where indicated, cells were treated with 50 !M MDC, 50 !M Z-
Don, 10 !M AG1478, 1.0 !M doxorubicin, and 100 ng/ml EGF. 
 
Tumor analysis 
Tissue array slides composed of paraffin embedded sections of normal brain samples and human 
primary brain tumors of various grades (#GL208; U.S. Biomax) were subjected to 
immunohistochemical analysis. Briefly, the slides were deparaffinized by baking them at 60°C 
for 30 min and then rehydrating them in water containing 3% hydrogen peroxide for 30 min. 
After washing with phosphate buffered saline (PBS), the slides were boiled for 10 min in a 10 
mM sodium citrate buffer (pH 6.0) and allowed to cool. The slides were then blocked with 2.5% 
horse serum and with Avidin/Biotin blocking solutions. The tissue arrays were incubated with a 
tTG, EGFR, or phospho-EGFR antibody, followed by a biotinylated secondary antibody and 
treatment with the Elite ABC reagent for 30 min. After washing with PBS, the slides were 
processed with chromogen solution. Lastly, the slides were dehydrated and mounted. The 
resulting staining obtained with each antibody was quantified using ImageJ software. 
 
REMBRANDT (Repository of Molecular Brain Neoplasia Data) analysis 
The REMBRANDT database (http://caintegrator.nci.nih.gov/rembrandt) was used to correlate 
tTG expression levels in brain tumors with patient survival rates. The parameters were set to 
include those brain tumor samples (343 gliomas or 181 glioblastomas) with a 2-fold or greater 
increase or a 2-fold or greater decrease in tTG expression.  The results were presented as Kaplan-
Meier Survival Plots. 
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 TCGA analysis 
tTG transcript levels in glioblastoma patient samples deposited in TCGA (https://tcga-
data.nci.nih.gov/tcga/) were analyzed using the cBio Cancer Genomics Portal (z-score of 0.5). 
The percentage of patients with increased tTG levels were plotted for each glioblastoma sub-
type. 
 
Immunoblot analysis and immunoprecipitation 
Cells were lysed with cell-lysis buffer (25 mM Tris, 100 mM NaCl, 1% Triton X-100, 1 mM 
EDTA, 1 mM DTT, 1 mM Na3VO4, 1 mM !-glycerolphosphate, 1 "g/mL leupeptin and 1 "g/mL 
aprotinin). The extracts were resolved by SDS-PAGE and transferred onto PVDF membranes. 
The membranes were incubated with primary antibodies diluted in TBST (20 mM Tris, 135 mM 
NaCl, and 0.02% Tween 20). Horseradish-peroxidase-conjugated secondary antibodies were 
used to detect the primary antibodies followed by exposure to ECL reagent. For 
immunoprecipitations, cell extracts (600 µg) were incubated with a particular antibody for 2 h, 
followed by the addition of Protein-G beads for 1 h. The beads were washed with cell-lysis 
buffer before being subjected to immunoblot analysis. 
 
Soft agar colony formation assays 
Cells (3X103) were suspended in growth medium supplemented without or with the indicated 
inhibitors and 0.3% agarose and plated on top of a layer of growth medium containing 0.6% 
agarose in a six-well plate. The growth medium and inhibitors were replenished on the cultures 
every fourth day, and after 10 days of growth the colonies that formed were counted and 
graphed. 
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 Apoptotic assays 
Cultures of cells were placed in serum-free medium containing various combinations of 
doxorubicin and MDC. After 1 day, the cells were collected and stained with DAPI for 
visualization by fluorescence microscopy. Cells undergoing apoptosis were identified by nuclei 
condensation/blebbing. 
 
Transamidation activity assays 
Cell extracts (15 µg of each) were incubated in a buffer containing 10 mM DTT, 10 mM CaCl2, 
and 50 µM BPA for 10 min. The reactions were stopped with the addition of Laemmli sample 
buffer, followed by boiling, and then the proteins were resolved on a SDS-PAGE gel, transferred 
to PDVF membranes, and blocked overnight in BBST (100 mM boric acid, 20 mM sodium 
borate, 0.01% SDS, 0.01% Tween 20, and 80 mM NaCl) containing 10% bovine serum albumin. 
The membranes were incubated with horseradish-peroxidase-conjugated streptavidin, diluted at 
1:2000 in BBST containing 5% BSA for 1 h, followed by extensive washing with BBST. The 
proteins that incorporated BPA were visualized on x-ray film after exposing the membranes to 
ECL reagent. 
 
Cell surface protein isolation assays 
Cell surface EGFR was isolated using the cell surface protein isolation kit according to the 
manufacturer’s protocol (Pierce). Briefly, U87 cells exposed to different culturing conditions 
were incubated with a cell-impermeable biotinylation reagent that labels the exposed primary 
amines of proteins expressed on the cell surface before being lysed. The EGFR was then 
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 immunoprecipitated from the extracts and the cell surface EGFR was detected using HRP-
streptavidin. 
 
BODIPY-GTP binding assays 
Recombinant tTG (600 nM final concentration) was added into buffer containing 1 mM 
BODIPY-GTP, 50 mM Tris-HCl, 2 mM DTT and 1 mM EDTA. Fluorescence changes were 
measured using a Varian eclipse spectrofluorimeter. The excitation and emission wavelengths for 
BODIPY fluorescence were set at 504 nm and 520 nm, respectively. 
 
Trypsin digestion assays 
The recombinant tTG proteins (3 µg of each) were combined with 80 ng of trypsin in a buffer 
containing 20 mM Tris, 300 mM NaCl and 10% glycerol.  The reaction was carried-out on ice 
for 2 h and stopped with the addition of Laemmli sample buffer, followed by boiling. The 
proteins were then resolved by SDS-PAGE and the gels were stained with Coomassie blue to 
visualize the proteins. 
 
In vitro binding assays 
Purified, recombinant His-tagged, wild-type tTG, or one of the mutant forms of tTG, was 
combined without or with purified, GST-tagged c-Cbl (1.0 !g of each protein) in a tube and 
rotated at 4°C for 2 h. Glutathione-coated agarose beads were then added to each tube for an 
additional 60 min, at which time the precipitated complexes were subjected to immunoblot 
analysis using tTG and c-Cbl antibodies. 
 

 REFERENCES 
 
1. Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, 
W. C., Ligon, K. L., Louis, D. N., Brennan, C., Chin, L., DePinho, R. A., and Cavenee, W. K. 
(2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment, Genes & 
development 21, 2683-2710. 
2. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., 
Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, 
S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., and Mirimanoff, 
R. O. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, The 
New England journal of medicine 352, 987-996. 
3. Jiang, D., Ying, W., Lu, Y., Wan, J., Zhai, Y., Liu, W., Zhu, Y., Qiu, Z., Qian, X., and 
He, F. (2003) Identification of metastasis-associated proteins by proteomic analysis and 
functional exploration of interleukin-18 in metastasis, Proteomics 3, 724-737. 
4. Jiang, W. G., Ablin, R., Douglas-Jones, A., and Mansel, R. E. (2003) Expression of 
transglutaminases in human breast cancer and their possible clinical significance, Oncology 
reports 10, 2039-2044. 
5. Kim, D. S., Choi, Y. B., Han, B. G., Park, S. Y., Jeon, Y., Kim, D. H., Ahn, E. R., Shin, 
J. E., Lee, B. I., Lee, H., Hong, K. M., and Kim, S. Y. (2011) Cancer cells promote survival 
through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking, Oncogene 
30, 4780-4790. 
6. Li, B., Antonyak, M. A., Druso, J. E., Cheng, L., Nikitin, A. Y., and Cerione, R. A. 
(2010) EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling 
pathway leading to Src activation, Proceedings of the National Academy of Sciences of the 
United States of America 107, 1408-1413. 
7. Lund-Johansen, M., Bjerkvig, R., Humphrey, P. A., Bigner, S. H., Bigner, D. D., and 
Laerum, O. D. (1990) Effect of epidermal growth factor on glioma cell growth, migration, and 
invasion in vitro, Cancer Res 50, 6039-6044. 
8. Rousselet, E., Traver, S., Monnet, Y., Perrin, A., Mandjee, N., Hild, A., Hirsch, E. C., 
Zheng, T. S., and Hunot, S. (2012) Tumor Necrosis Factor-Like Weak Inducer of Apoptosis 
Induces Astrocyte Proliferation through the Activation of Transforming-Growth Factor-
alpha/Epidermal Growth Factor Receptor Signaling Pathway, Molecular pharmacology 82, 948-
957. 
9. Moscatello, D. K., Montgomery, R. B., Sundareshan, P., McDanel, H., Wong, M. Y., and 
Wong, A. J. (1996) Transformational and altered signal transduction by a naturally occurring 
mutant EGF receptor, Oncogene 13, 85-96. 

 10. Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, 
K., Saya, H., Hirano, H., Kuratsu, J., Oka, K., Ishimaru, Y., and Ushio, Y. (2003) Prognostic 
value of epidermal growth factor receptor in patients with glioblastoma multiforme, Cancer Res 
63, 6962-6970. 
11. Umesh, S., Tandon, A., Santosh, V., Anandh, B., Sampath, S., Chandramouli, B. A., and 
Sastry Kolluri, V. R. (2009) Clinical and immunohistochemical prognostic factors in adult 
glioblastoma patients, Clinical neuropathology 28, 362-372. 
12. Guillaudeau, A., Durand, K., Pommepuy, I., Robert, S., Chaunavel, A., Lacorre, S., 
DeArmas, R., Bourtoumieux, S., El Demery, M., Moreau, J. J., and Labrousse, F. (2009) 
Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent 
in situ hybridization, Applied immunohistochemistry & molecular morphology : AIMM / official 
publication of the Society for Applied Immunohistochemistry 17, 220-226. 
13. Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., 
Waterfield, M. D., Ullrich, A., and Schlessinger, J. (1985) Amplification, enhanced expression 
and possible rearrangement of EGF receptor gene in primary human brain tumours of glial 
origin, Nature 313, 144-147. 
14. Miyoshi, N., Ishii, H., Mimori, K., Tanaka, F., Hitora, T., Tei, M., Sekimoto, M., Doki, 
Y., and Mori, M. (2010) TGM2 Is a Novel Marker for Prognosis and Therapeutic Target in 
Colorectal Cancer, Annals of surgical oncology 17, 967-972. 
15. Singer, C. F., Hudelist, G., Walter, I., Rueckliniger, E., Czerwenka, K., Kubista, E., and 
Huber, A. V. (2006) Tissue array-based expression of transglutaminase-2 in human breast and 
ovarian cancer, Clin Exp Metastasis 23, 33-39. 
16. Verma, A., Wang, H., Manavathi, B., Fok, J. Y., Mann, A. P., Kumar, R., and Mehta, K. 
(2006) Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and 
its implications in drug resistance and metastasis, Cancer Res 66, 10525-10533. 
17. Li, B., Cerione, R. A., and Antonyak, M. (2011) Tissue transglutaminase and its role in 
human cancer progression, Advances in enzymology and related areas of molecular biology 78, 
247-293. 
18. Antonyak, M. A., Li, B., Regan, A. D., Feng, Q., Dusaban, S. S., and Cerione, R. A. 
(2009) Tissue transglutaminase is an essential participant in the epidermal growth factor-
stimulated signaling pathway leading to cancer cell migration and invasion, The Journal of 
biological chemistry 284, 17914-17925. 
19. Boroughs, L. K., Antonyak, M. A., Johnson, J. L., and Cerione, R. A. (2011) A unique 
role for heat shock protein 70 and its binding partner tissue transglutaminase in cancer cell 
migration, The Journal of biological chemistry 286, 37094-37107. 
20. Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, 
C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., 
Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H. S., Hodgson, J. G., 

 James, C. D., Sarkaria, J. N., Brennan, C., Kahn, A., Spellman, P. T., Wilson, R. K., Speed, T. 
P., Gray, J. W., Meyerson, M., Getz, G., Perou, C. M., and Hayes, D. N. (2010) Integrated 
genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by 
abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer cell 17, 98-110. 
21. Quaranta, M., Divella, R., Daniele, A., Di Tardo, S., Venneri, M. T., Lolli, I., and 
Troccoli, G. (2007) Epidermal growth factor receptor serum levels and prognostic value in 
malignant gliomas, Tumori 93, 275-280. 
22. Antonyak, M. A., Miller, A. M., Jansen, J. M., Boehm, J. E., Balkman, C. E., Wakshlag, 
J. J., Page, R. L., and Cerione, R. A. (2004) Augmentation of tissue transglutaminase expression 
and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast 
cancer cells, The Journal of biological chemistry 279, 41461-41467. 
23. Qian, X., Ren, Y., Shi, Z., Long, L., Pu, P., Sheng, J., Yuan, X., and Kang, C. (2012) 
Sequence-Dependent Synergistic Inhibition of Human Glioma Cell Lines by Combined 
Temozolomide and miR-21 Inhibitor Gene Therapy, Molecular pharmaceutics. 
24. Ren, Y., Zhou, X., Mei, M., Yuan, X. B., Han, L., Wang, G. X., Jia, Z. F., Xu, P., Pu, P. 
Y., and Kang, C. S. (2010) MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 
(PTEN-mutant) and LN229 (PTEN-wild type) to taxol, BMC cancer 10, 27. 
25. Weaver, K. D., Yeyeodu, S., Cusack, J. C., Jr., Baldwin, A. S., Jr., and Ewend, M. G. 
(2003) Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B 
in human gliomas, Journal of neuro-oncology 61, 187-196. 
26. Mizoguchi, M., Betensky, R. A., Batchelor, T. T., Bernay, D. C., Louis, D. N., and Nutt, 
C. L. (2006) Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: 
correlation with EGFR status, tumor grade, and survival, Journal of neuropathology and 
experimental neurology 65, 1181-1188. 
27. Hu, J., Jo, M., Cavenee, W. K., Furnari, F., VandenBerg, S. R., and Gonias, S. L. (2011) 
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant 
III supports survival and growth of glioblastoma cells, Proceedings of the National Academy of 
Sciences of the United States of America 108, 15984-15989. 
28. Antonyak, M. A., Kenyon, L. C., Godwin, A. K., James, D. C., Emlet, D. R., Okamoto, 
I., Tnani, M., Holgado-Madruga, M., Moscatello, D. K., and Wong, A. J. (2002) Elevated JNK 
activation contributes to the pathogenesis of human brain tumors, Oncogene 21, 5038-5046. 
29. Huang, P. H., Xu, A. M., and White, F. M. (2009) Oncogenic EGFR signaling networks 
in glioma, Science signaling 2, re6. 
30. Han, W., Zhang, T., Yu, H., Foulke, J. G., and Tang, C. K. (2006) Hypophosphorylation 
of residue Y1045 leads to defective downregulation of EGFRvIII, Cancer biology & therapy 5, 
1361-1368. 

 31. Levkowitz, G., Waterman, H., Zamir, E., Kam, Z., Oved, S., Langdon, W. Y., Beguinot, 
L., Geiger, B., and Yarden, Y. (1998) c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination 
of the epidermal growth factor receptor, Genes & development 12, 3663-3674. 
32. Waterman, H., Levkowitz, G., Alroy, I., and Yarden, Y. (1999) The RING finger of c-
Cbl mediates desensitization of the epidermal growth factor receptor, The Journal of biological 
chemistry 274, 22151-22154. 
33. Datta, S., Antonyak, M. A., and Cerione, R. A. (2006) Importance of Ca(2+)-dependent 
transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-
induced apoptosis, Biochemistry 45, 13163-13174. 
34. Datta, S., Antonyak, M. A., and Cerione, R. A. (2007) GTP-binding-defective forms of 
tissue transglutaminase trigger cell death, Biochemistry 46, 14819-14829. 
35. Liu, S., Cerione, R. A., and Clardy, J. (2002) Structural basis for the guanine nucleotide-
binding activity of tissue transglutaminase and its regulation of transamidation activity, 
Proceedings of the National Academy of Sciences of the United States of America. 99, 2743-
2747. 
36. Pinkas, D. M., Strop, P., Brunger, A. T., and Khosla, C. (2007) Transglutaminase 2 
undergoes a large conformational change upon activation, PLoS Biol 5, e327. 
37. Frederick, L., Wang, X. Y., Eley, G., and James, C. D. (2000) Diversity and frequency of 
epidermal growth factor receptor mutations in human glioblastomas, Cancer Res 60, 1383-1387. 
38. Layfield, L. J., Willmore, C., Tripp, S., Jones, C., and Jensen, R. L. (2006) Epidermal 
growth factor receptor gene amplification and protein expression in glioblastoma multiforme: 
prognostic significance and relationship to other prognostic factors, Applied 
immunohistochemistry & molecular morphology : AIMM / official publication of the Society for 
Applied Immunohistochemistry 14, 91-96. 
39. Jung, Y., Joo, K. M., Seong, D. H., Choi, Y. L., Kong, D. S., Kim, Y., Kim, M. H., Jin, 
J., Suh, Y. L., Seol, H. J., Shin, C. S., Lee, J. I., Kim, J. H., Song, S. Y., and Nam, D. H. (2012) 
Identification of prognostic biomarkers for glioblastomas using protein expression profiling, 
International journal of oncology 40, 1122-1132. 
40. Vivanco, I., Rohle, D., Versele, M., Iwanami, A., Kuga, D., Oldrini, B., Tanaka, K., 
Dang, J., Kubek, S., Palaskas, N., Hsueh, T., Evans, M., Mulholland, D., Wolle, D., Rajasekaran, 
S., Rajasekaran, A., Liau, L. M., Cloughesy, T. F., Dikic, I., Brennan, C., Wu, H., Mischel, P. S., 
Perera, T., and Mellinghoff, I. K. (2010) The phosphatase and tensin homolog regulates 
epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation, 
Proceedings of the National Academy of Sciences of the United States of America 107, 6459-
6464. 
41. Furnari, F. B., Lin, H., Huang, H. S., and Cavenee, W. K. (1997) Growth suppression of 
glioma cells by PTEN requires a functional phosphatase catalytic domain, Proceedings of the 
National Academy of Sciences of the United States of America 94, 12479-12484. 

CHAPTER 3   
Studies on the Regulation of tTG Conformation 
 
Abstract 
Tissue transglutaminase (tTG) is a dual-function acyl transferase/GTP-binding protein 
that has been implicated in the regulation of many physiological processes as well as in the 
development of various disease conditions.  Previous structural and biochemical studies have 
revealed that tTG can exist in two conformational states, which might have important 
ramifications on its functions.  Under normal physiological conditions, tTG is bound to GTP or 
GDP and adopts a closed, enzymatically-inactive configuration that has been shown to promote 
cell growth and survival.  In contrast, in response to cellular stresses, tTG releases its bound 
nucleotide and assumes a more extended, open conformation.  In this state, tTG is enzymatically 
active and has been shown to induce cell death.  Given that the open and closed conformations of 
tTG can give rise to opposing cellular outcomes (cell survival v.s. apoptosis), we set out to better 
understand the molecular mechanisms that regulate the ability of tTG to adopt these two different 
conformations.  Here we identified two pairs of intramolecular interactions that are important for 
maintaining tTG in its closed configuration.  Specifically, two hydrogen bonds were formed 
between residues K677 and N681 in the most C-terminal !-barrel domain and residues W254 
and D434 localized in the catalytic core domain of tTG.  When these residues were mutated, it 
caused tTG to adopt an open conformation that triggered a strong apoptotic response in cells.  
These findings provide some new insights into how tTG is maintained in its closed 
conformation, and raise the intriguing possibility that approaches causing tTG to adopt an open 
conformation may be used as an effective therapy to kill cancer cells that over-express tTG. 
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Introduction 
Tissue transglutaminase (tTG) is a member of a family of enzymes that are best known 
for their ability to catalyze the calcium-dependent post-translational modification of proteins by 
forming an irreversible amide bond between two proteins or between a protein and a polyamine 
(i.e. transamidation/crosslinking activity) (1, 2).  Another function of tTG involves its ability to 
bind to and hydrolyze GTP, similar to other classical GTP-binding proteins (3, 4).  Both the 
transamidation and GTP-binding/hydrolysis activities of tTG have been shown to participate in 
many physiological processes, including cellular differentiation, wound healing, and extra-
cellular matrix stabilization (5, 6).  However, aberrant tTG expression and activities have also 
been shown to contribute to the development of various disease conditions, including human 
malignancies that are characterized by chemoresistance, and neurodegenerative disorders that are 
characterized by cell death (7, 8).  Therefore, understanding how tTG can impact cellular events 
that give rise to cell survival in some cases and cell death in others becomes an important 
question, especially since targeting tTG as a strategy to treat cancer and neurodegenerative 
disorders, such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, has been 
proposed (9-11).  
Normally, tTG is tightly regulated at both its level of expression and activation.  tTG 
expression in cells is typically low, but can be up-regulated by growth factor stimulation, the 
induction of cellular differentiation, as well as in response to various cellular insults (12-14).  
Once expressed in cells, the transamidation and the GTPase activities of tTG are subjected to 
further regulation.  Structural studies have shown that GDP or GTP binding to tTG causes it to 
adopt a compact, closed conformation that prevents it from functioning as a crosslinking enzyme 
(15, 16).  In this conformation, the C-terminal end of tTG folds over onto itself and blocks 
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substrate access to its enzymatic active site.  However, under stressful conditions, decreases in 
cellular energy levels and increases in intracellular Ca2+ concentrations cause tTG to loosen its 
binding to nucleotide (GTP or GDP), causing the C-terminus of tTG to move away from the 
catalytic active site (17, 18).  Therefore, the “open” conformation of tTG is enzymatically active 
and can catalyze the crosslinking reactions.  
Several lines of evidence have shown that these two conformational states of tTG can 
have profoundly different effects on cells.  For example, the closed conformation of tTG is 
believed to promote cellular processes that are consistent with the transformed phenotypes, 
including promoting cell growth and survival.  This has been born out in work carried out by our 
laboratory and others where it was shown that the ectopic expression of wild type tTG, which 
primarily adopts a closed conformation, in either normal (non-transformed) or cancer cell lines 
protects them from apoptosis induced by serum-deprivation or chemotherapy (19, 20).  
Moreover, in the previous chapter in this thesis, I showed that tTG contributes to the oncogenic 
transformation of aggressive brain cancer cells by prolonging the signaling lifetime of the EGFR, 
and that tTG can only exert this effect when it is in the closed conformation. 
On the other hand, the “open conformation” of tTG appears to have much different 
effects on cells.  This is exemplified in experiments where expressing a GTP-binding defective 
form of tTG (tTG R580K), which is believed to adopt an open conformation because it is no 
longer susceptible to the regulation by GTP or GDP, in cells for extended periods of time 
induces a potent cell death response (16).  Although this outcome was initially believed to be due 
to the un-regulated enzymatic activity exhibited by the tTG R580K mutant, this was 
subsequently proven not to be the case, as changing the active site cysteine to a valine in the tTG 
R580K background (thus generating an open form of tTG that is defective of crosslinking 
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activity) still induced cell death.  Consistent with this idea, an alternatively spliced variant form 
of tTG called tTG-Short (tTG-S), which is often detected in the brains of Alzheimer’s disease 
patients and exhibits greatly reduced transamidation activity, has also been shown to potently 
induce cell death (21, 22).  Because this variant form of tTG lacks the C-terminal !-barrel 
domains, it is predicted to adopt the open conformation, thus explaining the detrimental effects it 
has on cells.   
Here we set out to gain a deeper understanding of the mechanisms that regulate the 
ability of tTG to adopt the closed v.s. the open conformation.  To this end, we first showed that 
the GTP-binding defective form of tTG, tTG R580K, indeed adopts the “open” conformation in 
solution using small angle x-ray scattering analysis (SAXS).  We then looked for important 
intramolecular interactions that help keep tTG in its closed conformational state, and identified 
two pairs of hydrogen bonds formed between the C-terminal 15 amino acids of tTG and its 
catalytic core domain that were essential for maintaining tTG in the closed conformation.  When 
we disrupted these interactions by site directed-mutagenesis, tTG was shown to constitutively 
adopt the open conformation and trigger an apoptotic response in cells.  
 
Results 
tTG is a multifunctional protein composed of four distinct domains, including a N-
terminal !-sandwich domain, a catalytic core domain, followed by two C-terminal !-barrel 
domains (Figure 3.1A) (15).  X-ray crystallographic studies revealed that tTG can exist in one of 
two different conformational states.  When tTG is bound to nucleotide (i.e. GDP), it adopts a 
“closed” conformational state where the C-terminal !-barrels fold over and cover its catalytic 
core domain (Figure 3.1B, left panel, PDB: 1KV3) (15).  In this state, substrate access to the 
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Figure 3.1.  tTG adopts two different conformational states. 
(A) Graphic representation of tTG.  tTG is composed of four distinct domains; including a N-
terminal !-sandwich (blue), a catalytic core (green), followed by !-barrel 1 (orange) and !-barrel 
2 (red) at its C-terminus.  The numbers indicate the amino acids of each domain. 
(B) The x-ray crystal structures representing the open and closed conformations of tTG.  The 
domains in the structures are labeled as follow; the N-terminal !-sandwich (N), the catalytic core 
(core), and the two C-terminal !-barrels (!1 and !2).  tTG adopts a closed conformation when it 
is bound to GDP (PDB: 1KV3) (left panel), or an open conformation when it is covalently 
modified with a substrate mimetic gluten peptide (PDB: 2Q3Z) (right panel).  GDP and the 
gluten peptide are shown in sticks and colored in blue and red, respectively. 
(C) Purified recombinant forms of wild type tTG (tTG WT) and tTG R580K (3.0 !g of each 
protein) were incubated without or with trypsin for 2 hours before being resolved by SDS-PAGE 
and then stained with Coomassie blue to visualize the proteins.  Note that the tTG R580K mutant 
is more susceptible to trypsin cleavage than tTG WT. 
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transamidation active site of tTG is blocked, thus preventing tTG from functioning as a 
crosslinking enzyme.  However, in another structure solved when tTG is not bound to nucleotide 
(GTP or GDP) and covalently modified with a substrate-mimetic gluten peptide, tTG adopts a 
dramatically different “open” conformation (Figure 3.1B, right panel, PDB: 2Q3Z) (23).  In this 
case, the C-terminal !-barrel domains of tTG move away from the catalytic core domain and 
allow substrate access to the transamidation active site.  Therefore, the open conformation 
represents the enzymatically active state of tTG.   
Since the closed state of tTG promotes cell growth and survival, while the open state of 
tTG induces cell death, we set out to better understand the intramolecular mechanisms that 
influence tTG’s ability to transition between these two conformations.  Based on our findings 
shown in Figure 2.6C in the previous chapter, and again here in Figure 3.1C, recombinant wild 
type tTG is largely insensitive to trypsin cleavage (compare the first two lanes).  This is in 
contrast to a form of tTG that is defective in GTP binding due to mutation of an arginine residue, 
essential for coordinating GTP, to a lysine residue (tTG R580K), which shows increased 
sensitivity to trypsin digestion (Figure 3.1C, compare the third and the fourth lane).  Based on 
these results, we predict that wild type tTG primarily adopts a closed conformation that is 
insensitive to trypsin proteolysis, and tTG R580K adopts an open conformation and is more 
accessible for trypsin digestion.  
To further verify that tTG R580K assumes an open conformation and wild type tTG 
adopts a closed conformation, we performed small angle x-ray scattering analysis (SAXS) on 
these two forms of tTG, to gain additional information about the overall size and shape of the 
macromolecules in solution.  The Rg values for wild type tTG and tTG R580K were 32.7 Å and 
42.5 Å respectively (Figure 3.2).  Molecular weight calculations using scattering profiles from 
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Figure 3.2.  SAXS analysis on wild type tTG and the tTG R580K mutant. 
(A) SAXS analysis for wild type tTG (tTG WT).  A monomeric model derived from the crystal 
structure of GDP-bound wild type tTG (PDB: 1KV3) was fitted into the calculated SAXS 
envelope, with the N-terminal !-sandwich and the catalytic core domains colored in blue, and the 
two C-terminal !-barrel domains colored in red (left panel).  A cartoon representation shows the 
superimposition of the fitted model (blue and red) onto the structure of wild type tTG bound to 
GDP (PDB:1KV3, yellow color) (middle panel).  The experimental scattering profiles from 
SAXS are shown as blue dots, and the scattering profile for the GDP-bound wild type tTG 
structure (PDB: 1KV3) is shown as a green line (right panel).  
(B) SAXS analysis for the tTG R580K mutant (tTG R580K).  Two monomeric models derived 
from a substrate-bound wild type tTG crystal structure (PDB: 2Q3Z) were fitted into the 
calculated SAXS envelope for tTG R580K in a head to tail fashion.  The N-terminal !-sandwich 
and the catalytic core domains of the fitted models are colored in blue, and the two C-terminal !-
barrel domains are colored in red (left panel).  A cartoon representation shows the 
superimposition of one of the monomers in the fitted model (blue and red) onto the structure of 
the substrate-bound tTG (PDB: 2Q3Z, yellow color) (middle panel).  The experimental scattering 
profiles from SAXS are shown as blue dots, and the scattering profile for the substrate-bound 
wild type tTG structure (PDB: 2Q3Z) is shown as a green line (right panel).  
*SAXS data presented in Figure 3.2 is performed by Garima Singh. 
 
  
121
!"#$%"$
!"#$&'()*$
"#%"+,-!$
"#%"+./0$
$$$$$$$$$$$$$$1$)+2$
&3$45.$$1$67+8$9$
&3$:;<:$$1$6=+>$9
F
"#&*+,-!$
"#&*+./0$
$$$$$$$$$$$$$$$1$)+'$
&3$45.$$$1$?'+6!9$
&3$:;<:$$$1$?7+'$9$
F
@$
A$
122
SAXS data for tTG R580K showed that it exists as a homodimer in solution with a calculated 
molecular weight of 153.4 kDa, while wild type tTG exists as a monomer with a calculated 
molecular weight of 86.1 kDa.  After we applied an unbiased approach of preparing all possible 
models using available tTG structures and tested which of these best reflects the experimental 
scattering curve, we found that a monomer of a closed conformation of tTG (PDB: 1KV3) fits 
well for the SAXS envelope calculated for wild type tTG, with a !2 value of 0.9 (Figure 3.2A), 
and a dimer in an open conformation (PDB: 2Q3Z) fits well for the envelope calculated for the 
tTG R580K mutant, with a low !2 value of 0.5 (Figure 3.2B).  These data further validated our 
previous finding that the guanine nucleotide-binding defective tTG R580K mutant adopts a more 
extended configuration, while wild type tTG assumes a more compact conformation.  
It’s been reported that forms of tTG that exhibit an open conformation have deleterious 
effects on cell viability (16).  As shown in Figure 3.3A, ectopic expression of tTG R580K in 
NIH3T3 mouse fibroblasts resulted in ~20% of the cells undergoing apoptosis, as readout by 
nuclear condensation and blebbing.  Over-expression of wild type tTG in these cells, however, 
had no significant effect on their apoptotic rate compared to untransfected (mock) controls.  The 
apoptotic-promoting ability of ectopically expressed tTG R580K is accompanied by a time-
dependent selection against its expression.  When wild type tTG is introduced into NIH3T3 
mouse fibroblast cells, its expression is detected by 12 hours after transfection, and persists in the 
cells for at least 2 days (Figure 3.3B, first five lanes).  However, when we performed the same 
experiment with tTG R580K, this mutant form of tTG showed a rapid and progressive loss of 
expression in NIH3T3 cells.  The maximal expression level of tTG R580K, which occurred 12 
hours after transfection, is much lower compared to the expression level of wild type tTG at the 
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Figure 3.3.  The open conformational state of tTG induces cell death. 
(A) Immunofluorescence using a Myc antibody and DAPI (to stain nuclei) was performed on 
NIH3T3 cells that were either mock transfected or transfected with wild type tTG or one of the 
indicated mutant forms of tTG.  Cells ectopically expressing the Myc-tagged tTG constructs 
were then further evaluated for apoptosis, as indicated by the presence of condensed or blebbed 
nuclei.  Representative fluorescent pictures of cells expressing Myc-tagged wild type tTG or 
Myc-tagged tTG R580K are shown (left panel).  Percentages of transfectants undergoing 
apoptosis were plotted (right panel).  Data are represented as mean ± SEM. 
(B) Extracts from NIH3T3 cell ectopically expressing the vector-alone, wild type tTG (tTG WT), 
or tTG R580K were collected after the indicated hours of transfection.  The extracts were then 
immunoblotted (IB) with Myc and actin antibodies. 
(C) Cell extracts collected from 293T cells expressing different forms of Myc-tagged tTG were 
immunoblotted (IB) with Myc and actin antibodies (bottom two panels), as well as were assayed 
for their enzymatic transamidation activity, as read out by the incorporation of biotinylated 
pentylamine (BPA) into cellular lysate proteins (top panel). 
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same time point (Figure 3.3B, compare the second and the sixth lane), and by 48 hours post 
transfection, no exogenous expression was detected (Figure 3.3B, last lane).  
Loss of nucleotide-binding capability leads to the greatly enhanced transamidation 
activity exhibited by tTG R580K, compared to wild type tTG, as measured in an in vitro 
transamidation activity assay (Figure 3.3C, compare the first two lanes) (12).  Considering that 
the irreversible post-translational modification of proteins catalyzed by tTG can have profound 
effects on their structure and function, and that the elevated transamidation activity of tTG has 
been associated with pathogenic protein aggregation in the development of neurodegenerative 
disorders, one would suspect that the apoptosis-inducing effects of tTG R580K may result from 
the uncontrolled crosslinking of essential proteins in cells (24).  However, this turned out not to 
be the case, as a double mutant form of tTG which lacks both GTP-binding and enzymatic 
transamidation activities (by mutation of the essential active site cysteine to valine) (Figure 3.3C, 
fourth lane), referred to as tTG R580K/C277V, induced apoptosis in NIH3T3 cells to a similar 
extent as the tTG R580K mutant (Figure 3.3A, compare the third and fourth bars) (20).  This 
indicates that the excessive transamidation activity associated with tTG R580K is not required 
for its cytotoxic effects.  Rather, these findings suggest that it is the ability of this mutant form of 
tTG to adopt the open conformation that mediates its cytotoxicity. 
The crystal structure of wild type tTG bound to GDP shows that the GDP molecule 
resides in a cleft between the catalytic core domain and the first !-barrel domain (Figure 3.1B, 
left panel).  This hinge region undergoes a dramatic conformational change when tTG transitions 
from the closed conformation to the open state, as the two C-terminal !-barrels swing 120° away 
from the catalytic core domain to form a fully extended molecule (Figure 3.1B, right panel).  
Taking into account that the tTG R580K mutant is in the open conformation, it would suggest 
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that the nucleotide bound to tTG makes key contacts with the hinge region to help bring the C-
terminal !-barrels and the catalytic core domain into close proximity, thereby stabilizing tTG in 
its compact conformation and inhibiting its transamidation activity.   
Previous studies from our group showed that a splice variant of tTG called tTG-short 
(tTG-S), which lacks the C-terminal 138 amino acids, also induced a strong apoptotic response 
when expressed in cells (Figure 3.3A, fifth bar) (21).  These results suggest that tTG-S likely 
adopts an open conformation similar to tTG R580K.  Interestingly, the C-terminal region missing 
in tTG-S correspond to half of the first C-terminal !-barrel and all of the second !-barrel of tTG, 
which makes close contacts with the core domain when tTG is in its closed configuration.  
However, these points of contacts are absent in the open conformation due to the movement of 
the C-terminal !-barrels away from the catalytic core domain.  This raises the possibility that the 
intramolecular interactions that occur between the C-terminal !-barrel 2 and the core domain of 
tTG may play an important role in stabilizing tTG in its closed conformation.   
To test this hypothesis, we started by generating a series of tTG C-terminal truncation 
mutants (Figure 3.4A), with the idea being that by eliminating residues that are important for the 
ability of the C-terminal !-barrel to make contacts with the catalytic core, it will cause tTG to 
assume the open configuration.  Because forms of tTG that are in the open conformation (i.e. 
tTG R580K and tTG-S) consistently promote apoptosis, we used this as a readout to indicate 
whether a given tTG mutant was in the open or closed state.  Figure 3.4B showed that by 
truncating just the last 15 amino acids (amino acids 673-687) of tTG, we were able to generate a 
tTG mutant (i.e. tTG 672) that caused NIH3T3 cells to undergo apoptosis to a similar extent as 
the tTG R580K mutant.  The C-terminal 15 amino acids of tTG correspond to the last !-sheet in 
the second !-barrel domain in tTG (Figure 3.4C, left panel).  Close examination of the GDP-
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Figure 3.4.  C-terminal !-barrel 2 is involved in stabilizing tTG in its closed conformation. 
(A) Schematic representation of wild type tTG and two different C-terminally truncated forms of 
tTG that were generated.  The numbers represent the amino acids, and the truncation sites of the 
tTG mutants are indicated. 
(B) Apoptotic assays were performed on NIH3T3 cells that were mock transfected or transfected 
with the indicated forms of tTG.  The percentages of transfectants undergoing apoptosis, as read 
out by nuclear condensation/blebbing, were determined and then plotted.  Data shown represents 
mean ± SEM. 
(C) The C-terminal 15 amino acids of tTG (residues 673-687) are highlighted in purple in the x-
ray crystal structure of tTG bound to GDP (left panel).  Two pairs of hydrogen bonds formed 
between residues N681 and D434, and between residues K677 and W254, are shown in red with 
participating residues shown in sticks.  Distances for each interaction are also highlighted (right 
panel). 
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bound tTG structure revealed that two pairs of hydrogen bonds are formed between residue K677 
in the !-barrel 2 domain and residue W254 in the catalytic core domain, and between residue 
N681 in the !-barrel 2 domain and residue D434 in the catalytic core domain (Figure 3.4C, right 
panel).   
To test whether the formation of these hydrogen bonds contributes to the stabilization of 
the closed conformation of tTG, we mutated each of the four participating residues to an alanine 
residue to disrupt these intramolecular interactions.  We hypothesized that if these two pairs of 
hydrogen bonds play an important part in stabilizing tTG’s closed conformation, then generating 
mutations that block their formation should cause tTG to assume an open conformation and 
induce apoptosis.  Figure 3.5A shows that this was indeed the case, as ectopic expression of any 
one of these point mutants in NIH3T3 cells caused the cells to undergo apoptosis to a similar 
extent as tTG R580K, indicating that they all adopt an open conformation.   
To further verify this finding, we decided to compare these mutant forms to wild type 
tTG and tTG R580K in trypsin proteolysis assays.  Attempts to generate recombinant forms of 
tTG D434A and tTG K677A mutants were not successful, likely because these proteins are 
unstable and degrade rapidly.  However, we were able to generate the recombinant forms of tTG 
W254A and tTG N681A, and tested their sensitivity to trypsin digestion.  As shown in Figure 
3.5B, both the tTG W254A and N681A mutants were almost completely digested after 
incubation with trypsin, confirming that they both adopt the open conformation in vitro.   
Next, we examined whether the transamidation and GTP-binding activities of tTG were 
influenced by these mutations.  HEK293T cells were transfected with either wild type tTG or one 
of the mutant forms of tTG and then were lysed.  The transamidation activity associated with 
each of the cell extracts was then determined.  Figure 3.5C shows that the W245A mutant 
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Figure 3.5.  Identification of the key residues that keep tTG in a closed conformation.  
(A) Apoptotic assays were performed on NIH3T3 cells that were either mock transfected or 
transfected with the indicated forms of tTG.  The percentages of transfectants undergoing 
apoptosis, as read out by nuclear condensation/blebbing, were determined and then plotted.  Data 
shown represents mean ± SEM. 
(B) Purified recombinant forms of wild type tTG (tTG WT), tTG R580K, tTG W254A and tTG 
N681A (3.0 !g of each protein) were incubated without or with trypsin for 2 hours before being 
resolved by SDS-PAGE and then stained with Coomassie blue to visualize the proteins.  Note 
that the tTG R580K, tTG W254A, and tTG N681A mutants are efficiently cleaved by trypsin, 
while tTG WT is not. 
(C) Cell extracts collected from 293T cells ectopically expressing the different forms of Myc-
tagged tTG were immunoblotted (IB) with Myc and actin antibodies (bottom two panels), as well 
as assayed for their enzymatic transamidation activity (top panel). 
(D) Purified recombinant forms of wild type tTG (tTG WT), tTG W254A, and tTG N681A were 
incubated with BODIPY-GTP and the resulting changes in fluorescence caused by the binding of 
BODIPY-GTP to the recombinant proteins were determined and plotted. These experiments 
were performed at least three separate times, each yielding similar results. 
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abolished the enzymatic activity of tTG, and the D434A mutation greatly reduced it (Figure 
3.5C, compare the second and third lanes to the first lane).  Both W254 and D434 are localized 
in the catalytic core domain and are within close proximity to the catalytic active site (i.e. C277) 
of tTG.  Thus, mutations at these two sites may perturb local structures within the catalytic 
domain and explain why the enzymatic activity of these mutant forms of tTG is inhibited.  
Mutations in the more distant C-terminal residues (i.e. tTG K677A and N681A), however, had a 
more modest effect on the enzymatic activity of tTG, and interestingly, the tTG N681A mutant 
reproducibly showed slightly elevated transamidation activity compared to wild type tTG (Figure 
3.5C, compared the fourth and fifth lanes to the first lane).  This suggests that the tTG N681A 
mutant is primarily adopting an open conformation, making the catalytic active site more 
accessible for substrate binding and exhibiting enhanced enzymatic activity, similar to tTG 
R580K (Figure 3.3C).   
In addition to examining the transamidation activities of these tTG mutants, we also 
assayed the nucleotide-binding activities of the two available recombinant mutants (tTG W254A 
and tTG N681A) utilizing the fluorescent GTP analog BODIPY-GTP (16).  Figure 3.5D shows 
that wild type tTG has a high affinity for BODIPY-GTP, as indicated by the significant 
fluorescence change upon BODIPY-GTP binding to wild type tTG, consistent with previous 
studies (16).  However, both the tTG W254A mutant and the tTG N681A mutant showed little 
activity to bind guanine nucleotide.  This suggests that, even with an intact nucleotide-binding 
pocket, the mutant forms of tTG that adopt the open conformational state are incapable of 
efficiently associating with GTP. 
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Discussion 
Under different cellular conditions, tTG can either assume a nucleotide-bound closed 
conformation, or a nucleotide-free open conformation, and the two distinct conformational states 
of tTG are often linked to opposing cellular outcomes (cell survival v.s. cell death).  In order to 
gain more understanding of the regulation of tTG, we set out to identify the intramolecular 
mechanisms that regulate the transition of tTG between these two distinct states.   
X-ray structural studies predict that a nucleotide-free form of tTG is likely to assume an 
open conformation (23).  We showed using trypsin proteolysis assays and SAXS analysis that a 
nucleotide-binding defective form of tTG, tTG R580K, indeed adopts a constitutive open 
conformation, while wild type tTG primarily assumes a compact, closed conformation.  Previous 
studies showed that the ectopic expression of tTG R580K induces a strong apoptotic response in 
cells (16).  Due to loss of the nucleotide-binding capability, and it adopting an open 
conformation, tTG R580K exhibits elevated crosslinking activity compared with wild type tTG.  
Considering that elevated tTG expression and activation have often been detected in several 
forms of neurodegenerative disorders, characterized by aggregation of pathogenic proteins, it 
was originally thought that the ability of tTG R580K to induce cell death resulted from the tTG-
catalyzed crosslinking of essential cellular proteins in an uncontrolled manner.  However, we 
found that the tTG R580K/C277V double mutant, which is incapable of binding GTP (and 
adopts an open conformation) and catalyzing transamidation activity, caused an apoptotic 
response similar to tTG R580K (16).  This led us to realize that the cytotoxic phenotype 
exhibited by tTG R580K was not due to its uncontrolled enzymatic activity, but more likely is 
somehow coupled to the specific open conformation that it adopts.  
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Searching for other regulatory mechanisms that help to maintain tTG in the closed 
conformation, we turned to previous studies performed on an isoform of tTG, namely tTG-short 
(tTG-S).  tTG-S is a naturally occurring splice variant of tTG which is identical to wild type (full 
length) tTG except it is lacking the C-terminal 138 amino acids.  Previous studies showed that 
this isoform of tTG has virtually no transamidation activity and is unable to bind GTP, however, 
it is a strong inducer of apoptosis (21).  This information is important for a couple of reasons.  
First, it provided us with another piece of evidence that the de-regulated transamidation activity 
is not required for the cytotoxic effects induced by tTG, as initially suspected from studies on 
neurodegenerative diseases, or that of the tTG R580K mutant when it is expressed in cells.  
Secondly, the similar cytotoxic phenotype shared by tTG-S and tTG R580K indicates that tTG-S 
possibly adopts a similar open configuration as tTG R580K.   
Subsequently, we found that in the GDP-bound compact tTG structure, the 138 amino 
acids that are missing in tTG-S correspond to the C-terminal !-barrel 2 and half of the !-barrel 1, 
which make close contacts with the catalytic core domain of tTG.  Based on this information, we 
proposed that the missing C-terminal end in tTG-S is involved in the stabilization of the closed 
conformational state of tTG.  By generating a series of mutant forms of tTG, we found that two 
pairs of hydrogen bonds formed between residues K677 and N681 residing within the last !-
sheet of tTG, with residues W254 and D434 that lie within its catalytic core domain, play an 
important role in maintaining tTG in its closed conformation.  Mutation of any of these residues 
disrupted the intramolecular interactions and caused tTG to assume an open conformational 
state.  When expressed in cells, these mutants induced apoptosis.   
Overall, these findings indicate that an intricate relationship exists between the nucleotide 
binding status of tTG, the conformational state that it assumes, and the balance between cell 
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survival and death.  Both nucleotide binding and the intramolecular interactions that occur 
between the second !-barrel of tTG (!-barrel 2) and its catalytic core domain are required to 
keep tTG in its compact conformation.  Disrupting GDP/GTP binding by mutating the residues 
within the nucleotide binding pocket (i.e. tTG R580K), or disrupting the C-terminal interactions 
by mutating the participating residues, both lead to destabilization of the closed conformation of 
tTG and cause it to adopt an open state.  
tTG has been shown to participate in various signaling pathways that contribute to the 
oncogenic transformation of cancer cells.  In these cases, tTG is proposed to be in the nucleotide-
bound, enzymatically inactive state, where it can function as a signaling scaffold protein and 
engage in different signaling pathways.  Studies from my previous data chapter (Chapter 2) 
showed that intracellular tTG is able to extend the signaling lifetime of the epidermal growth 
factor receptor by interfering with its down-regulation.  Other studies have shown that tTG can 
stimulate NF"B, Src kinase and PI3-kinase activities (20, 25, Boroughs et al., unpublished).  All 
of these actions of tTG collectively lead to an array of beneficial cellular outcomes, including 
enhanced cell proliferation, migration, and resistance to apoptosis (12, 26, 27).  However, how 
the open conformational state of tTG causes such adverse effects when expressed in cells is not 
fully understood.  It is believed that when tTG is in the open conformation, it may selectively 
associate with and inactivate a cellular protein(s) that is important for maintaining cell viability, 
or it may activate a pro-apoptotic signaling pathway and trigger cell death.  We are currently 
investigating these possibilities, as described further in the next chapter.   
tTG is attractive to consider as a therapeutic target to treat a host of conditions/diseases 
including cancer and neurodegenerative disorders for several reasons.  Much of this interest 
stems from the fact that tTG is up-regulated in disease states, but is not essential for normal 
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developmental processes.  tTG knockout mice have no developmental defects and grow to 
normal size, indicating that tTG is not essential for early development nor for basic cellular 
functions (28, 29).  Moreover, tTG expression is absent or occurs at relatively low levels in many 
normal cell lineages, whereas it is greatly up-regulated in several types of cancer and 
neurodegenerative disorders (7, 18).  Therefore, eliminating abnormal tTG functions could 
provide a promising targeted strategy for treating these disease conditions.   
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Materials 
Cell-culture reagents and Lipofectamine were obtained from Invitrogen.  BPA was purchased 
from Pierce.  Actin antibody was from Thermo Fisher Scientific, and Myc antibody was from 
Covance.  
 
Cell culture and transfections 
HEK293T cells were maintained in DMEM medium supplemented with 10% fetal bovine serum 
(FBS), while NIH3T3 mouse fibroblasts were maintained in DMEM supplemented with the 10% 
calf serum (CS).  The tTG expression constructs were introduced into cells using Lipofectamine.  
 
Trypsin digestion assays 
The recombinant tTG proteins (3 µg of each) were combined with 80 ng of trypsin in a buffer 
containing 20 mM Tris, 300 mM NaCl and 10% glycerol.  The reaction was carried-out on ice 
for 2 h and stopped with the addition of Laemmli sample buffer, followed by boiling.  The 
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proteins were then resolved by SDS-PAGE and the gels were stained with Coomassie blue to 
visualize the proteins. 
 
Immunofluorescence and apoptotic assays 
The cells were fixed with PBS containing 3.7% formaldehyde and then permeabilized with PBS 
containing 0.1% Triton X-100.  After blocking in PBS containing 10% BSA, the cells were 
incubated with primary anti-Myc antibody for 2 h.  The cells were then incubated with Oregon 
Green 488-conjugated secondary antibody (Molecular Probes) and DAPI (to stain nuclei) for 1 h.  
Following the secondary incubations, the cells were washed extensively with PBS, mounted, and 
visualized using the 20X objective on a Zeiss Axioskop fluorescent microscope.  Cells 
undergoing apoptosis were identified by nuclei condensation/blebbing.  The images were 
captured and processed using IPLAB. 
 
Immunoblot analysis 
Cells were lysed with cell-lysis buffer (25 mM Tris, 100 mM NaCl, 1% Triton X-100, 1 mM 
EDTA, 1 mM DTT, 1 mM Na3VO4, 1 mM !-glycerolphosphate, 1 "g/mL leupeptin and 1 "g/mL 
aprotinin).  The extracts were resolved by SDS-PAGE and transferred onto PVDF membranes.  
The membranes were incubated with primary antibodies diluted in TBST (20 mM Tris, 135 mM 
NaCl, and 0.02% Tween 20).  Horseradish-peroxidase-conjugated secondary antibodies were 
used to detect the primary antibodies followed by exposure to ECL reagent.  
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Transamidation activity assays 
Cell extracts (15 µg of each) were incubated in a buffer containing 10 mM DTT, 10 mM CaCl2, 
and 50 µM BPA for 10 min.  The reactions were stopped with the addition of Laemmli sample 
buffer, followed by boiling, and then the proteins were resolved on a SDS-PAGE gel, transferred 
to PDVF membranes, and blocked overnight in BBST (100 mM boric acid, 20 mM sodium 
borate, 0.01% SDS, 0.01% Tween 20, and 80 mM NaCl) containing 10% bovine serum albumin.  
The membranes were incubated with horseradish-peroxidase-conjugated streptavidin, diluted at 
1:2000 in BBST containing 5% BSA for 1 h, followed by extensive washing with BBST.  The 
proteins that incorporated BPA were visualized on x-ray film after exposing the membranes to 
ECL reagent. 
 
BODIPY-GTP binding assays 
Recombinant tTG (600 nM final concentration) was added into buffer containing 1 mM 
BODIPY-GTP, 50 mM Tris-HCl, 2 mM DTT and 1 mM EDTA.  Fluorescence changes were 
measured using a Varian eclipse spectrofluorimeter.  The excitation and emission wavelengths 
for BODIPY fluorescence were set at 504 nm and 520 nm, respectively. 
 
Small-Angle X-Ray Scattering (SAXS) Data Collection and Processing.  
SAXS experiments were carried out at the Cornell High Energy Synchrotron Source (CHESS, 
beamline F2) at an electron energy of 10 KeV.  Protein samples were prepared in 20 mM HEPES 
buffer (pH 7.4) containing 300 mM NaCl, 2% Glycerol and 0.5 mM TCEP at concentrations 
between 1 and 10 mg/ml.  Ten data frames for each sample and for the corresponding buffer 
solution were collected.  The data were corrected for background scattering, averaged, and scaled 
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using the program BioXtas.  Rg values were estimated from the Guinier plots.  Scattering data 
with Smax!Rg < 1.3, computed from the Guinier plots at the low-angle regions, were used for 
further analysis.  Kratky plots were used to assess the folded state of the proteins and overall data 
quality.  Only data showing no sign of radiation damage or aggregation based on Guinier plots 
were used for further analysis.  Due to concentration-dependent aggregation, only samples with 
concentrations between 1 mg/ml – 2.5 mg/ml were used to compose the scattering curve in the 
low-q range.  Data were analyzed using the GNOM and CRYSOL programs.  Using an indirect 
Fourier transform (IFT) method as implemented in the GNOM program, the intra-particle 
distance distribution function, p(r), Dmax, the radius of gyration of the protein, Rg, the integral 
properties of p(r), and the extrapolated forward scattering intensity, I (q = 0) (in a relative scale), 
were determined from the experimental scattering data profiles.  Using the P(r) function as the 
target, SAXS-based shape reconstructions were carried out with the DAMMIF program.  Ten 
independent models of each were calculated and averaged using DAMAVER.  The envelopes of 
the reconstructed shapes were superposed onto their respective models with SUBCOMB.  
SASREF can minimize the discrepancy between the experimental scattering data, and the 
theoretical scattering curve calculated from an x-ray structural model of the individual 
components, thus optimizing position and orientation of the proteins.  Using the SASREF 
program, the components of the monomer/dimer equilibrium of tissue transglutaminase (PDB: 
1KV3, 2Q3Z) were treated as rigid bodies, and the modeling of domains to the SAXS data set 
was done through a simulated annealing protocol.  SASREF simulations were computed and 
compared visually. CRYSOL was used to calculate the theoretical scattering curves for models 
where the subunits were manually positioned.  
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CHAPTER 4 
Conclusions 
 
Increasing amounts of evidence suggest that tTG, a dual function acyl 
transferase/GTPase, contributes to the progression of various types of human cancers.  The 
expression level of tTG is up-regulated in breast, pancreatic and colon cancers, and over-
expression/activation of tTG has been shown to promote cancer cell migration, proliferation and 
survival (1-5).  In this thesis, I set out to expand upon our understanding of how tTG contributes 
to the malignant transformation of cancer cells.   
In the first study presented in Chapter 2, I delineated a novel mechanism through which 
tTG promotes brain tumor progression.  In this study, I showed that tTG expression is up-
regulated in 70% of high grade brain tumors, making it one of the most commonly de-regulated 
genes in this type of cancer.  Moreover, tTG expression was negatively correlated with patient 
survival.  Elevated expression level of tTG was also detected in several human glioblastoma cell 
lines, where it was shown to play an indispensible role in their transforming capabilities.  We 
then discovered that tTG contributes to the transformed phenotypes of these aggressive brain 
cancer cells by extending the signaling lifetime of the EGFR.  !
Aberrant EGFR activation is a hallmark of glioblastomas (6, 7).  Gene amplification 
and/or activating mutations of the EGFR can account for the excessive signaling activities of the 
EGFR in some glioblastomas (8).  However, these mechanisms can not explain EGFR over-
expression and/or hyper-activation in all cases, indicating that additional mechanisms that give 
rise to enhanced EGFR expression and signaling activity must exist.  We found that tTG is 
responsible for one such mechanism through its ability to attenuate EGFR down-regulation.  

EGFR ubiquitylation mediated by the E3-ubiquitin ligase c-Cbl is an important step in the down-
regulation of the activated EGFR (9, 10).  We showed that tTG can bind to c-Cbl both in vitro 
and in vivo, and functionally inactivate c-Cbl’s E3-ubiquitin ligase activity. 
Studies from several groups, including our laboratory, have reported mechanisms where 
enhanced EGFR signaling is achieved by disrupting the down-regulation of the EGFR.  
Phosphatase and tensin homolog (PTEN) and Ephrin receptor A5 (EphrinA5) are both tumor 
suppressors which are frequently downregulated or deleted in primary brain tumors (11, 12).  
Studies showed that PTEN and EphA5 can stabilize the complex formation between the EGFR 
and c-Cbl, therefore promoting the ubiquitylation and down-regulation of the activated EGFRs.  
However, the detailed mechanisms by which PTEN and EphA5 regulate c-Cbl function are not 
known.  Our group reported that the Cool-1 (cloned-out of library 1) protein, a signaling 
molecule downstream of the EGFR, also plays a key role in regulating EGFR degradation (13).  
EGFR-dependent phosphorylation of Cool-1 enables it to function as an activator of Cdc42, 
which can then form a ternary complex with Cool-1 and c-Cbl, and delay c-Cbl-catalyzed EGFR 
down-regulation.  This complex is normally transient, however, sustained Cool-1 
phosphorylation was observed when a constitutively active form of the Src kinase was 
introduced into cells, which led to defective EGFR turnover and aberrant growth.   
In our studies, we not only identified tTG as a key regulator of EGFR signaling and brain 
tumor cellular transformation, but we also uncovered the mechanism by which tTG affects c-Cbl 
function.  The association between tTG and c-Cbl occurs only when tTG adopts a specific closed 
conformational state, i.e. when tTG is bound to GDP or GTP.  Mutant forms of tTG that adopt an 
open conformational state, or treatment of tTG with certain inhibitors that induce the open state, 

disrupt the complex formation between tTG and c-Cbl and block the ability of tTG to enhance 
EGFR signaling activities. 
While it has been known for some time that tTG can function as a downstream target of 
the EGFR and is important for the growth and survival activities of the EGFR, the findings 
showing that tTG can regulate EGFR signaling lifetime was quite unexpected.  They also raise 
the question as to whether the excessive EGFR signaling activities observed in these brain cancer 
cells are responsible for the elevated expression and activation of tTG, which in effect would 
give rise to a feed-back loop.  One piece of evidence that supports this idea comes from a 
proteomic study that was published a few years ago (14).  In this study, the protein expression 
profiles were compared between U87 glioma cells stably expressing either a vector-only control 
or the constitutively active and highly oncogenic EGFRvIII.  tTG was found to be one of only 
four proteins whose expression were significantly up-regulated by EGFRvIII.  This would 
suggest that the constitutive EGFR signaling activity observed in these glioblastoma cells 
contributes at least in part to the up-regulation of tTG expression.  Possibly by increasing tTG 
expression in cells and blocking the actions of c-Cbl, the EGFR develops a mechanism to 
maintain its signaling potential in these aggressive brain tumors.  
A few other interesting questions also arise from this study.  First, does tTG have a 
broader impact and influence the half-life of other receptor tyrosine kinases besides EGFR in 
brain tumors?  The fact that tTG has no significant influence on the overall ubiquitylation levels 
in these glioblastoma cells suggests that the tTG-mediated inhibition of ubiquitylation is a 
targeted process.  The finding that tTG exerts its impact primarily on the E3-ubiqutin ligase c-
Cbl further supports this idea, as the specificity of the ubiquitylation processes is primarily 
determined at the level of the E3-ubiquitin ligase and substrate recognition (15).  However, c-Cbl 

has been reported to function as the E3-ubiquitin ligase that down-regulates several other 
receptor tyrosine kinases and non-receptor tyrosine kinases, including the PDGFR, c-Met and 
Fyn, all of which have been implicated in glioblastoma (16-21).  Whether tTG is capable of 
modulating the signaling activities of these tyrosine kinases remains to be determined.  Also, 
whether the ability of tTG to regulate EGFR signaling holds true in cancer types other than brain 
tumors (i.e. breast cancer) needs to be examined.  
 We showed that tTG was only able to associate with c-Cbl and interfere with its ubiquitin 
ligase function when it is bound to nucleotide (GTP or GDP) and adopts the specific closed 
conformation.  This finding reminded us of the less studied GTP-binding/hydrolysis activity of 
tTG.  tTG, identified as a high molecular weight G-protein in the early 1990s, has been shown to 
mediate the signaling activities of a few cell surface receptors (22, 23).  The GTPase activity of 
tTG has not been extensively studied, partially due to the lack of similarity between tTG and the 
more traditional small GTPases or the large hetero-trimeric G-proteins.  At this time, no 
regulatory factors (GEFs or GAPs) have been identified for tTG.  However, what is in common 
between tTG and other GTP-binding proteins is that nucleotide association induces 
conformational changes within the molecule that have important ramifications for their 
functions.  In the case of the traditional small GTPases or hetero-trimeric G-proteins, the binding 
of nucleotides stabilizes the protein conformation, and cycling between the GTP- and GDP-
bound states causes local movement of conformationally-sensitive (switch) regions that are 
important for engaging or disengaging upstream receptors or downstream effectors.  In the case 
of tTG, nucleotide-free tTG and nucleotide-bound tTG adopt dramatically different 
configurations, as demonstrated by the two crystal structures for the GDP-bound and the 
nucleotide-free forms of wild type tTG (24, 25).  Moreover, the trypsin proteolysis studies that 

we performed on wild type tTG and tTG R580K mutant further demonstrated that tTG adopts a 
distinct conformation when it is bound to nucleotide. 
Under normal physiological conditions, intracellular tTG is most likely associated with 
GTP/GDP due to the high concentrations of GTP present in the cytosol, therefore it is most 
likely to be in the closed conformation.  However, under stressful conditions like those 
accompanying neurodegenerative disorders, energy depletion, loss of Ca2+ homeostasis, and the 
binding of Ca2+ to tTG cause a release of nucleotide, thus enabling tTG to adopt the open 
conformation.  Previous studies, as well as findings presented in Chapter 2, showed that the two 
conformational states of tTG are often engaged in different signaling pathways, leading to 
distinct cellular outcomes (cell survival v.s. cell death) (1, 26).  In chapter 3, we went on to 
further examine the regulatory mechanisms that control the transition of tTG between the two 
different states.   
In addition to nucleotide-binding regulating the opening and closing of tTG, we also 
identified intramolecular interactions that influence these conformational transitions.  
Specifically, two pairs of hydrogen bonds formed between the !-barrel 2 domain and the 
catalytic core domain of tTG were shown to stabilize the closed conformation of tTG.  
Disruption of these interactions, either by individually mutating the residues that are involved in 
making these hydrogen bonds, or by deleting this entire region as occurs in tTG-S, a splice 
variant expressed in neurodegenerative disorders, resulted in forms of tTG that adopt an open 
conformation and induce cell death, a phenotype similar to the GTP-binding defective tTG (tTG 
R580K) mutant, which we have shown by SAXS analysis to also adopt an open conformation.  
How the open form of tTG promotes apoptosis is still unclear.  The increased 
crosslinking activity of tTG due to the loss of GTP binding observed with the tTG R580K 

mutant, together with the aggregation of pathogenic proteins detected in neurodegenerative 
disorders, suggested that the uncontrolled crosslinking activity might be responsible for the 
ability of tTG to induce cell death.  However, we proved that this cannot explain the apoptotic 
effects of the GTP-binding defective tTG (tTG R580K) mutant, as the R580K/C277V double 
mutant  (that lacks both GTP-binding and crosslinking activities) induced cell death to a similar 
extent as tTG R580K, indicating that other unique capabilities that tTG acquires when it adopts 
the open conformation contributes to its cytotoxicity.  We now suspect that when tTG assumes 
its extended conformation, it might become capable of associating with and functionally 
inactivating proteins that are essential for maintaining cell viability, therefore disrupting normal 
cellular processes and promoting cell death.  
To test this idea, we are now looking for proteins that preferentially associate with the 
open form of tTG (i.e. tTG R580K), using two different approaches.  In one such approach, we 
performed pull-down experiments using recombinant forms of wild type tTG and tTG R580K, 
representing two different states of tTG, and screened for specific binding partners in NIH3T3 
fibroblast cell lysates.  We found that a protein with an apparent molecular weight of ~120 kDa 
preferentially associated with tTG R580K in these experiments.  The protein band was excised 
from the gel and analyzed by mass spectrometry.  The top hits from the mass spectrometry 
analysis are listed in Table 4.1, and some them are potentially interesting with regard to the 
apoptotic-inducing actions of tTG R580K.  For example, the #1 hit, FERM domain containing 
4A (FRMD4A), and the #10 hit, FERMRhoGEF, both contain the FERM (4.1, Ezrin, Radixin 
and moesin) domain, which is a protein module implicated in localizing proteins to the plasma 
membrane (27, 28).  This indicates that the FERM domain may represent a high-affinity binding 
motif for the open form of tTG.  Moreover, recent studies have reported the role of FRMD4A in 

Table 4.1.  The identified components of the ~120 kDa band that preferentially associated 
with tTG R580K from mass spectrometry. 
 
  

prot_hit 
num prot_acc prot_desc 
prot 
score 
prot 
mass 
prot 
cover 
prot 
pi 
emPAI 
 
molar 
% 
1 gi|40254210 FERM domain containing 4A [Mus musculus] 1344 115771 38.4 9.09 1.12 2.95 
2 gi|6678826 minichromosome maintenance deficient 2 mitotin [Mus musculus] 1253 102668 37.2 5.52 1.26 3.31 
3 gi|26986595 ring finger protein 40 [Mus musculus] 1140 114835 34.8 6.11 1.19 3.13 
4 gi|33859650 membrane bound C2 domain containing protein [Mus musculus] 901 121707 34.2 5.63 1.05 2.76 
5 gi|16716569 protease, serine, 1 [Mus musculus] 886 26802 16.7 4.75 1.02 2.68 
6 gi|33859829 ring finger protein 20 [Mus musculus] 855 114135 22.7 5.74 0.62 1.63 
7 gi|111607496 Janus kinase 1 [Mus musculus] 733 135149 24.5 7.48 0.73 1.92 
8 gi|33942089 ataxin 2-like [Mus musculus] 686 110865 21.2 8.94 0.79 2.08 
9 gi|85662406 cytoplasmic linker 2 isoform b [Mus musculus] 662 112300 28 6.13 0.68 1.79 
10 gi|110349752 FERMRhoGEF (Arhgef) and pleckstrin domain protein 1 [Mus musculus] 625 119599 30.1 7.88 0.67 1.76 
11 gi|124358959 TAO kinase 1 [Mus musculus] 609 116434 22.2 7.14 0.65 1.71 
12 gi|145966692 keratin complex 1, acidic, gene 1 [Mus musculus] 535 48911 23.6 4.87 1.19 3.13 
13 gi|149262435 PREDICTED: keratin complex 1, acidic, gene 3 [Mus musculus] 506 55405 19.5 5.21 0.78 2.05 
14 gi|13386238 keratin 34 [Mus musculus] 489 46185 22.4 4.76 1.29 3.39 
15 gi|149254026 PREDICTED: SEC31-like 1 [Mus musculus] 482 145123 15.6 8.09 0.28 0.74 
16 gi|112983636 keratin complex 1, acidic, gene 10 [Mus musculus] 477 57178 12.5 5 0.4 1.05 
17 gi|13386274 RIKEN cDNA 2310015J09 [Mus musculus] 419 47661 21.8 4.76 1.09 2.87 
18 gi|126116585 keratin complex 2, basic, gene 1 [Mus musculus] 401 66079 4.9 8.39 0.34 0.89 
19 gi|149261084 PREDICTED: TBP-interacting protein isoform 1 [Mus musculus] 373 160752 16.4 6.86 0.33 0.87 
20 gi|33563246 calpastatin [Mus musculus] 369 81620 24.5 5.24 0.37 0.97 
21 gi|7305031 erythrocyte protein band 4.1-like 3 [Mus musculus] 355 103731 22.7 5.2 0.45 1.18 
22 gi|8393684 keratin 35 [Mus musculus] 337 48984 20.7 4.76 0.92 2.42 
23 gi|9055218 formin binding protein 3 [Mus musculus] 336 108698 13.6 7.39 0.39 1.03 
24 gi|31980832 keratin complex 2, basic gene 18 [Mus musculus] 321 57377 23.9 6.19 1.06 2.79 
25 gi|6679134 neuropilin 1 [Mus musculus] 315 104266 12.7 5.67 0.28 0.74 
26 gi|20911031 keratin 5 [Mus musculus] 295 61957 16.7 7.59 0.51 1.34 
27 gi|30794206 splicing factor 3b, subunit 2 [Mus musculus] 291 98237 21.6 5.46 0.39 1.03 
28 gi|84781771 trypsin 10 [Mus musculus] 289 26888 18.7 5.5 0.42 1.10 
29 gi|71043961 trypsinogen 7 [Mus musculus] 282 27089 4.9 8.22 0.26 0.68 
30 gi|6678790 mannosidase 2, alpha 1 [Mus musculus] 282 132247 10.4 8.17 0.22 0.58 
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regulating cell polarity and promoting squamous cell carcinoma growth (29, 30).  It is worth 
examining whether the open form of tTG can disrupt cell polarity or Rho GTPase signaling by 
binding to these FERM domain-containing proteins.  A few other well-studied signaling 
molecules, including the #11 hit, the serine/threonine-protein kinase TAO1, and the #7 hit, Janus 
kinase 1 (JAK1), were also identified in this list.  Future work will focus on validating the 
interactions of these candidate proteins with open form of tTG and determining whether they are 
linked to its cytotoxic effects. 
In another approach, we tested proteins that are known to be essential for cell viability or 
promote cell survival, and determined whether they preferentially associate with tTG R580K, 
compared with wild type tTG.  We found that the protein GIT1/Cat-1 (G protein-coupled 
receptor kinase interacting ArfGAP 1/Cool associated tyrosine phosphorylated 1) strongly 
associated with tTG R580K and other open forms of tTG, but showed almost no affinity for wild 
type tTG (Figure 4.1A).  Cat-1 is best known for its roles in regulating cell shape and cell 
migration, by functioning as a scaffold protein and bringing various proteins together through its 
different protein binding motifs (31).  However, recent studies from our lab showed that Cat-1 
expression is up-regulated in human cervical cancer samples, and that it contributes to their 
transformed characteristics (32).  We found that knocking-down Cat-1 expression with siRNA in 
HeLa cells triggered a strong apoptotic response, similar to what we have observed when over-
expressing tTG R580K in these cells (Figure 4.1B).  Thus, an attractive working model is that 
the open form of tTG, by binding to and sequestering Cat-1, disrupts the normal signaling and 
cellular functions mediated by Cat-1 and therefore triggers cell death.  We are currently in the 
process of determing the domain on Cat-1 that binds to tTG R580K, with the hope being that 
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Figure 4.1.  Cat-1 binds to open forms of tTG. 
(A) Immunoprecipitations with a Myc antibody (IP: Myc) were performed on extracts from 293T 
cells transfected with V5-tagged Cat-1 and either Myc-tagged wild type tTG (WT) or with the 
indicated Myc-tagged mutant forms of tTG.  The resulting immuno-complexes, as well as the 
whole cell extracts collected (WCL), were immunoblotted (IB) with Myc and V5 antibodies. 
(B) Apoptotic assays were performed on HeLa cells that were transfected with control siRNA or 
a siRNA targeting Cat-1.  Percentages of apoptotic cells under each condition are plotted.  Data 
are represented as mean ± SEM. 
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these findings will allow us to generate mutant forms of Cat-1 that no longer interact with tTG 
and then examine how they influence cell viability.  
 
Closing Remarks 
An increasing number of studies over the past decade has greatly expanded our 
understanding of the biochemical, structural, and functional activities of tTG, an enzyme that 
was mostly recognized for its crosslinking activity, but is now appreciated to be a 
multifunctional protein that plays important roles in cell differentiation, ECM stabilization, 
neurodegeneration and cancer progression.  During the course of this thesis work, I have built 
upon these previous findings and identified a new role for tTG in promoting brain tumor 
progression, as well as uncovered the molecular mechanisms that regulate the transition of tTG 
between two functionally distinct states.  Hopefully, these new insights will help us to better 
understand the function and regulation of tTG, and provide some new possibilities for targeting 
aberrant tTG functions in the treatment of different disease conditions.  
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